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1. Introduction 
The discovery of human platelets takes a long time. It is not until 1880s that 
Bizzozero fulfilled a detailed description of it for the first time, following a more 
comprehensive study conducted with microscope (Brewer 2006), (De Gaetano 
2001). Platelets are small anucleate blood cells derived from megakaryocytes 
(MKs). They are formed from MKs’ cytoplasm fragments with the auxiliary of 
shear forces of circulating blood (George 2000). They lack genomic DNA since 
they are non-nucleated. However, platelet cytoplasm retains a large number of 
messenger RNA (mRNA), which is carried over from megakaryocytes, and 
maintain the survival and perform physiological functions of platelets (Harrison 
and Goodall 2008), (Rowley et al. 2012). The normal circulating human platelets 
are discoid in shape, with the average diameter of only 2.0 ~5.0 μm and the 
mean volume of 7 ~11 femtoliters (fl) (Gremmel et al. 2016), (Harrison 2005). 
Nevertheless, activated platelets change their shape to a sphere, and protrude 
their dendritic pseudopodia with the constriction of the microtubular ring and 
cytoskeletal reorganization (George 2000). Normally, an adult human produces 
100 billion platelets per day, and maintains the level of 150 to 350 × 109/L 
platelets in circulating blood. The production number can increase under some 
special circumstances, such as bleeding caused by vascular wall damage 
(George 2000), (Italiano 2008), (Kaushansky 2008). 
1.1 The physiological functions of platelets 
Undoubtedly, platelets participating in hemostasis following vascular injuries is 
considered to be their most important function (Broos et al. 2011). Under the 
physiological circumstances, platelets can survive for 10 days, and are 
decomposed and removed in spleen after senescence. They can flow freely in 
the lumen of blood vessel, and do not bond to each other or intact with blood 
7 
vessel wall (Aster 1966), (Gehrmann et al. 1972). However, injured vascular 
triggers platelet activation through a series of signalling cascades. Then 
activated platelets aggregate and adhere to the extracellular matrix until platelet 
plug formed at the injured site, (Broos et al. 2011), (Ni and Freedman 2003). 
Defective platelets can lead to a lot of diseases. For example, gray platelet 
syndrome and scott syndrome. In addition, activated platelets may also cause 
thrombus formation during the hemostasis, which plays a key role in stroke (Hou 
et al. 2015). Besides, platelets also contribute to coronary artery disease, 
peripheral vascular disease, host defense, Inflammation, tumor metastasis, and 
so on. (Sabrkhany et al. 2011), (Smyth et al. 2009), (Xu et al. 2016), (Yeaman 
2014). 
1.2 Platelet granules and bio-marker glycoproteins 
Platelets secretory granules are critical for such anucleate cells to perform 
physiological functions. There are three types of secretory granules in platelet 
cytoplasm: α-granules, dense granules and lysosomes. The first two types are 
more important and in larger number (George 2000). Platelet α-granules are 
derived from MKs. In matured α-granules, there are two types of predominant 
contents - membrane bound proteins and soluble proteins, such as P-selectin 
(CD62), fibrinogen, von Willebrand factor (vWF), some of chemokine and so on. 
Majority of them are from MKs, and then stored in granules vesicles. In addition, 
plasma-derived proteins are taken up by α-granules through the mechanism of 
endocytosis (Rendu and Brohard-Bohn 2001), (Blair and Flaumenhaft 2009). 
Platelet dense granules mainly contain some small molecules, such as calcium, 
ADP, ATP, serotonin and so on (King and Reed 2002). Although less is known 
about dense granules compare with α-granules, it is clear that these small 
molecules play important roles in platelet activation, aggregation and vascular 
remodeling. Upon the stimulation of injured vessels, rapidly elevated cytosolic 
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Ca2+ trigger release of dense granules contents by exocytosis. During this 
process, ADP can also further stimulate and activate platelets as an effective 
agonist (Morimoto et al. 1990), (Reed 2004), (Jones et al. 2011). 
With the development of electrophoresis technology, many platelet glycoproteins, 
such as GPIIb-IIIa, GPIa-IIa, GPIb-IX-V, GPVI and so on, have been reported 
over the past few decades. They play a key role in platelet interaction and 
combination with endothelial matrix during hemostasis (Nurden 2014). αIIbβ3, 
also known as GPIIb/IIIa, is the most important member of integrin glycoproteins 
family. They can be found in platelet α-granules, and are largely expressed and 
located at the surface of platelets after platelet activation. Moreover, this kind of 
glycoprotein account for about one-sixth of the total platelet membrane protein 
mass, and can be easily detected as a marker of platelet activation in vitro 
(Gremmel et al. 2016).  
Integrin αIIbβ3 contributes to platelet activation and aggregation as the receptor 
of fibrinogen and vWF. However, they have a low affinity for ligands in the resting 
platelets. When platelets are activated, the concentration level of intracellular 
Ca2+ rapidly elevate and thus triggers inside-out signalling cascades of integrin 
αIIbβ3, which changes the conformation of integrin protein binding site and 
results in the improvement of receptor-ligand affinity.(Broos et al. 2011). At the 
same time, extracellular ligands binding also activate the outside-in signalling of 
integrin. With the addition of more intermediate proteins and adapters, such as 
Rac, Rho GTPases, paxillin, Nck and so on, platelet cytoskeletal reorganization 
is promoted, which is important for platelet spreading, the stability of aggregation 
and clot retraction (Coller and Shattil 2008), (Ginsberg et al. 2005). 
Furthermore, glycoprotein P-selectin, another marker of platelet activation, is 
found in α-granule of resting platelets, which translocate rapidly to surface of 
platelets upon platelet activation(Garcia-Martinez et al. 2004). P-selectin 
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glycoprotein ligand 1 (PSGL-1) is the main ligand of P-selectin, which is 
expressed on the surface of endothelial cells and leukocytes. Besides, binding of 
ligand-receptor can subsequently lead to platelet aggregation and adhesion in 
hemostasis (Andre 2004), (Merten and Thiagarajan 2004). 
1.3 The mechanism of coagulation  
The paramount physiological function of platelets is contributing to cessation of 
bleeding by developing a hemostatic plug on the site of vascular injury. The 
coagulation mechanism is rather complicated. In early times, it is summarized as 
a cascade model that involves both extrinsic and intrinsic pathways. However, 
the cascade model cannot well explain hemostasis in vivo because of separate 
coagulation pathways. Later on, a cell-based model that describes the process 
of coagulating on three types (or states) of cell surfaces is presented and widely 
accepted, which contributes to a better understanding hemophilia (Monroe 
2002), (Hoffman and Monroe 2001).  
In this model, the whole process is divided into three overlapping steps: initiation, 
amplification and propagation (Fig.1.1). Briefly, the coagulation cascades starts 
with tissue factor (TF), which is released by TF-bearing cells on site of the 
injured blood vessel. In the initiation phase, cascades reaction generates small 
amount of thrombin (FIIa) as clotting factor Xa (FXa) binding to prothrombin (FII). 
This phase occurs on the surfaces of TF-bearing cells. During the amplification 
phase, thrombin further stimulates the feedback mechanism, while the platelet 
state conversion from resting to activation takes place. At the same time, many 
factors are activated at the surface of platelets, such as FIXa, FVIIIa, FVa. These 
activated factors lead to the formation of FXa/FVa complex at surface of 
activated platelets, which then combine with FII to produce a large number of 
thrombin. High concentration of thrombin can cleave fibrinogen into fibrin 
monomer, which eventually results in a stable fibrin clot on injured blood vessel 
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wall (Monroe 2002), (Eyre and Gamlin 2010), (Hoffman and Monroe 2007). 
 
Fig.1.1. Cell-based model of coagulation (Eyre and Gamlin 2010) 
1.4 The mechanism of platelet activation 
1.4.1 Platelet agonists and receptor pathways 
The activation of platelets starts with the binding of some agonists with specific 
receptors, which triggers downstream cascades of outside-in signalling as well 
as platelet activation (Goggs and Poole 2012). There are two major types of 
signalling pathways in platelets. The first is tyrosine kinase pathway, in which 
platelet activation relies on phosphorylation of tyrosine in common 
immunoreceptor tyrosine-based activation motif (ITAM) or hem-ITAM. Generally, 
this pathway can influence platelet adhesion and aggregation by regulating 
downstream signalling (Stegner and Nieswandt 2011), (Bergmeier and Stefanini 
2013).  
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FII FIIa (thrombin)
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A Typical example is GPVI, a collagen receptor, which forms a complex with 
FcR-γ chain to perform functions. The cascade reaction begins with 
phosphorylation of ITAM as well as Syk. Upon phospholipase Cγ2 (PLCγ2) 
activation, downstream PI3 kinase is further activated, which ultimately triggers 
Ca2+ mobilization, integrin αIIbβ3 activation and platelet aggregation (Stegner 
and Nieswandt 2011), (Watson et al. 2010). Besides, integrin αIIbβ3 and 
GPIb-V-IX also rely on tyrosine kinase pathway to activate platelets. The former 
can bind to fibrinogen, while the latter can bind to vWF (Watson et al. 2005), 
(Jackson et al. 2003). 
Moreover, most soluble agonists, such as ADP, thrombin, TxA2 and so on, 
mainly activate platelets through G-protein coupled receptor pathway. The 
ligand-receptor interaction trigger different downstream cascades by coupling 
different types of G protein, and further regulate platelet Ca2+ mobilization, shape 
change, and aggregation (Offermanns 2006). 
1.4.2 The effect of Ca2+ on platelet aggregation 
Cytosolic Ca2+ plays a key role in platelets as the second messenger. 
Agonists-induced cascades lead to rapid increase of cytosolic Ca2+ levels. High 
level of Ca2+ concentration can activate downstream mediator protein, which 
ultimately influences platelet full activation, aggregation, spreading and so on (Li 
et al. 2010), (Bergmeier and Stefanini 2009). 
Ca2+ and diacylglycerol (DAG)-regulated guanine nucleotide exchange factor I 
(CalDAG-GEFI) is one of the important Ca2+ binding proteins in platelets, which 
consists of two Ca2+-binding EF hand, one Ras exchange motif and one 
DAG-binding C1 domain. However, it only has a weak affinity with DAG (Guidetti 
et al. 2013). DAG is derived from phosphatidylinositol 4,5-trisphosphate (PIP2), 
which is hydrolyzed by PLCβ isoforms following agonist stimulation (Lian et al. 
2005). High concentration of cytosolic Ca2+ and DAG bind to CalDAG-GEFI 
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together, which further activate the small GTPase Rap1b. This process can be 
stopped by PKA-mediated inhibition mechanism (Subramanian et al. 2013) 
(Crittenden et al. 2004). Activated Rap1b is an important mediator for integrin 
activation of inside-out cascades signalling, which mediate αIIbβ3 activation by 
regulating protein complex of integrin β subunits tail (Zhang et al. 2011), 
(Guidetti and Torti 2012). The complex contains many kinds of proteins, such as 
Talin-1, Kindlin-3, RIAM and so on. It enhances affinity of integrin to ligand by 
disrupting the salt bridge between the two tails of αIIbβ3 subunits (Banno and 
Ginsberg 2008), (Lefort et al. 2012). 
Protein kinase C (PKC) is another important regulator of integrin activation via 
Ca2+ dependent approach. Typically, PKCα, an isoform of PKC family that also 
contains DAG and Ca2+ binding domain, can effectively regulate integrin αIIbβ3 
activation via interaction with Rap1 upon intracellular Ca2+ increase (Cifuni et al. 
2008), (Harper and Poole 2010), (Han et al. 2006). It is already well known that 
activated integrin promotes the binding of fibrinogen in circulating blood and 
leads to the platelet aggregation and adhesion under different shear conditions 
(Jackson 2007). 
1.4.3 The effect of Ca2+ on platelet secretion 
High concentration of intracellular Ca2+ regulates not only platelet aggregation 
but also secretion of platelet granules. Platelets release granule contents to 
respond to stimulation through Ca2+-induced exocytosis, which is a complex and 
unique process. Although a large number of researches have been reported, the 
mechanism of platelet exocytosis remains indistinct (Blair and Flaumenhaft 
2009). 
According to current studies, soluble N-ethylmaleimide sensitive factor 
attachment protein receptors (SNAREs), which are membrane-associated 
proteins, can be divided into two categories - target membranes (tSNAREs) and 
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vesicles associated proteins (vSNAREs). They mediate the release of platelet 
granule contents by fusing granule membrane with plasma membrane or open 
canalicular system (OCS) (Flaumenhaft 2017), (Huang and Whiteheart 2015). 
The increased intracellular Ca2+ can induce platelet shape change through the 
assembly of cytoskeletal F-actin, which subsequently enrich α-granules to 
membrane vesicles and membrane fragments (Woronowicz et al. 2010), (Ge et 
al. 2012). At the same time, the adaptor protein of F-actin, VARP, binds to 
related vSNAREs of α-granules (VAMP-7), and guide granules to contact and 
fuse with plasma membrane (Koseoglu et al. 2015). 
As is described above, PKC is activated following intracellular Ca2+ increase, 
which can phosphorylate many kinds of tSNAREs proteins and SNAREs-related 
regulators, such as SNAP-23, syntaxin 4, Munc-18, myristoylated alanine-rich C 
kinase substrate (MARCKS) and so on (Polgar et al. 2003), (Chung et al. 2000), 
(Schraw et al. 2003), (Elzagallaai et al. 2000). The phosphorylation of these 
proteins can directly or indirectly affect the formation of SNAREs complex during 
the fusion of membranes. In addition, Ca2+ activated PKC also regulate platelet 
secretion by interacting with downstream effector protein PKD2. However, this 
pathway only selectively regulates dense granule secretion according to 
Konopatskaya’s report (Konopatskaya et al. 2011). 
Munc13-4 is another story in platelet exocytosis. Generally, Munc13-4 regulates 
tSNAREs protein via Ca2+-dependent PKC pathway. However, it is possible to 
affect the fusion of membranes by binding and clustering phospholipid PS in 
response to direct interaction with Ca2+. Moreover, Ca2+-dependent 
Munc13-4-phospholipid helps stabilize dense granule in resting and activated 
platelets (Chicka et al. 2016). At the same time, Munc13-4 can also bind to the 
small GTPase Rab27 on granule surface. Such two-way combination could be 
another factor contributing to the stability of membrane fusion (Shirakawa et al. 
2004). 
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1.4.4 The effect of Ca2+ on platelet shape change 
Upon agonists stimulation, the contractile and reorganization of cytoskeletal 
systems can lead to platelet shape change via Ca2+-dependent and 
-independent signalling (Aslan 2017). Rapidly elevated intracellular Ca2+ binds to 
calmodulin firstly. Then the complex further activates myosin light-chain kinase 
(MLCK), which can initiate the mechanism of actin-myosin interaction of platelet 
shape change via the phosphorylation of myosin light-chain (Bauer et al. 1999). 
Furthermore, Ca2+ regulates cytoskeletal reorganization by binding activated 
actin to related proteins, such as gelsolin and calpain, which play a critical role in 
platelet spreading (Calaminus et al. 2008), (Kuchay et al. 2012), (Falet et al. 
2000). Ca2+-dependent actin cytoskeletal reorganization also contributes to the 
activation of integrin and platelet granules secretion according to the reports (Ge 
et al. 2012), (Falet 2017).  
1.4.5 Ca2+ stores and releases in platelets 
As is mentioned above, platelets rely on the increase of intracellular Ca2+ 
concentration ([Ca2+]i) in response to agonists stimulation, and the elevation of 
[Ca2+]i mainly results from the release of endogenous stores and influx of 
extracellular Ca2+. There are two independent intracellular stores in platelet 
cytoplasm. The first one is the dense tubular system (DTS), an endoplasmic 
reticulum (ER)-like membrane system, which is the major Ca2+ store (Gerrard et 
al. 1978). Sarco-ER Ca2+-ATPase (SERCA), an important member of the Ca2+ 
pump family on platelet DTS surface, can transport cytosolic Ca2+ into DTS 
compartments in ATP consumption-dependent manner (Flaumenhaft 2016). 
However, this process can be stopped by thapsigargin, a non-competitive 
inhibitor of SERCA (Hakii et al. 1986). Furthermore, the release of Ca2+  by DTS 
relies on the binding of inositol 1,4,5-trisphosphate (IP3) to IP3 receptor on DTS 
surface upon the stimulation of agonists, such as thrombin, ADP and so on, 
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which subsequently activate related Ca2+ channel to complete the process. 
(Jardin et al. 2008). 
The second Ca2+ store in platelets is lysosome related acidic organelles, 
including mitochondria and secretory granules (Jardin et al. 2008). Similarly, 
Ca2+ enter organelles via different SERCA isoforms, and can be blocked by high 
concentration of thapsigargin or 2,5-di-(t-butyl)-1,4-hydroquinone (TBHQ) 
(Rosado 2011). However, the release of intracellular Ca2+ of acidic organelles to 
cytosol relies on nicotinic acid adenine dinucleotide phosphate (NAADP) and 
membrane related receptors. This mechanism remains to be developed.(Coxon 
et al. 2012). 
1.4.6 Extracellular Ca2+ entry pathway 
The release of intracellular Ca2+ plays an important in the initial stage of platelet 
response to stimulation. However, the sustainable and stable functioning of 
platelets relies on the influx of a large amount of extracellular Ca2+ that rapidly 
refills the store depletion. Exogenous Ca2+ can enter cytosol across the platelet 
plasma membrane via a variety of pathways, such as the family of transient 
receptor potential cation channels (TRPCs), Na+/Ca2+ exchanger (NCX), 
ATP-gated P2X1 receptor (Sage et al. 2002), (Harper and Sage 2007), 
(Mahaut-Smith et al. 2011). These pathways are important to maintain Ca2+ 
balance in resting platelets and induce procoagulant activity upon the activation 
of platelets (Mahaut-Smith 2013). Yet, much attention to Ca2+ entry pathway was 
focused on store-operated Ca2+ entry (SOCE) in recent years, which can support 
massive of Ca2+ influx across the plasma membrane in platelets as well as many 
other cells (Prakriya and Lewis 2015). 
1.4.7 Store-operated Ca2+ channels of platelets 
The agonist-receptor interaction leads to the activation of phospholipase C via G 
proteins or tyrosine kinase signalling pathway. When PIP2 are hydrolyzed by 
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phospholipase C, IP3 is produced, which can bind to the receptors of DTS 
surface and ultimately empty Ca2+ stores. The depletion of Ca2+ pool results in 
the entry of extracellular Ca2+ through plasma membrane channels to refill the 
stores. This process was known as SOCE and reported by Putney in 1986 
(Putney 1986). However, it was not until 1992 that the existence of SOCE in 
platelets was proved for the first time (Sargeant et al. 1992).  
Extracellular Ca2+ refilling the stores via SOCE rely on store-operated Ca2+ 
channels (SOCs) of platelet plasma membrane. Researchers firstly focused on 
the TRPC family, which can contribute to SOCE in many other kinds of cells 
(Cheng et al. 2013). TRPC1 also express in human platelets, and involve in the 
regulation of platelet SOCE according to the report of Rosado et al (Rosado et al. 
2002). However, further experiments have demonstrated that TRPC1 is not the 
major SOC in platelets, as TRPC1 deficient mice still display fully intact SOCE 
(Varga-Szabo et al. 2008). TRPC1 and TRPC6 may indirectly regulate 
extracellular Ca2+ entry via interaction with stromal interaction molecule1 (STIM1) 
or Orai1. But the role of TRPC in platelet SOCE remains controversial until now 
(Jardin et al. 2008), (Jardin et al. 2009).  
In addition, Ca2+ release-activated Ca2+ (CRAC) channel is considered as the 
most important SOC for platelet SOCE in recent years (Lang et al. 2013). CRAC 
channel can rapidly regulate the entry of extracellular Ca2+ to refill the stores, 
thus plays a critical role in performing platelet Ca2+-dependent functions. 
1.4.8 CRAC channel of platelets 
Current studies show that the most attractive SOC channel is CRAC channel, 
which can regulate platelet SOCE via the interaction between the pore forming 
CRAC moiety (CRACM1) Orai1 and Ca2+ sensor STIM1 of platelet ER 
membrane (Fig.1.2) (Lang et al. 2013), (Braun et al. 2009). Orai protein family is 
divided into three kinds of isoforms, respectively termed as Orai1, Orai2 and 
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Orai3, all of which are found in human platelets utilizing real time PCR and 
Western blotting. However, the four transmembrane helices protein Orai1 has 
been identified as the most important CRAC channel protein in platelets (Lang et 
al. 2013), (Berna-Erro et al. 2012). Similarly, the STIM1 and STIM2 are also 
found in human platelet ER. Especially, STIM1 is the major isoform during 
STIM-induced SOCE (Berna-Erro et al. 2012).  
 
Fig.1.2. Orai1/STIM1 mediated SOCE and Ca
2+
 signaling in platelets 
(Bergmeier and Stefanini 2009) 
Following platelet activation and further depletion of ER Ca2+, Ca2+ 
sensitive-STIM1 can couple Orai1 of plasma membrane by changing its 
molecular conformational, which ultimately results in extracellular Ca2+ influx 
(Frischauf et al. 2008), (Braun et al. 2009). Platelets from Orai1R93W (partial 
mutation of Orai1) mice display reduced Ca2+ influx. At the same time, R93W 
mutation also causes impaired activation and phosphatidylserine (PS) exposure 
in response to agonists’ stimulation. However, this mutation did not effectively 
influence the platelets aggregation and adhesion in comparison with wild type 
mice (Bergmeier et al. 2009). The effect of STIM1/Orai1 on platelet SOCE was 
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further demonstrated in STIM1 and Orai1 deficient mice respectively. But the 
deficiency in Orai1 cannot entirely block the PS exposure and thrombus 
formation (Gilio et al. 2010). 
2-aminoethoxydiphenyl borate, a soluble inhibitor of Orai1, can effectively blunts 
platelet SOCE, and suppress Ca2+-dependent thrombus formation (van 
Kruchten et al. 2012), (Lang et al. 2015). In addition, STIM1/Orai1 mediated 
SOCE can also be blunted in platelets by their antibodies (Galan et al. 2009), or 
nonsteroidal estrogens after incubation (Dobrydneva et al. 2010).  
1.4.9 The regulation of STIM1/Orai1-dependent Ca2+ signalling in platelets 
The couple of STIM1/Orai1 plays a crucial role in platelet SOCE. However, the 
regulation mechanisms of them, as well as related Ca2+ signalling remain to be 
clarified. It was reported many years ago that Phosphoinositide 3-Kinase (PI3K) 
involves in the regulation of platelet functions. Gilio reports that it can strongly 
regulate GPVI-dependent [Ca2+]i elevation (Gilio et al. 2009). Orai1 protein 
abundance in human platelets increases significantly within a short time upon 
thrombin stimulation. At the same time, this process can also be effectively 
blunted by the inhibitor of PI3K (Munzer et al. 2013). PI3K signalling regulates 
multiple downstream signalling molecules in different cells, such as Akt (Protein 
kinase B, PKB) and serum- and glucocorticoid-inducible kinase 1 (SGK1) (Lang 
and Shumilina 2013). 
SGK1 is expressed in both platelets and megakaryocytes. The elevation of 
[Ca2+]i, and thus platelet activation as well as thrombus formation in vitro are 
significantly attenuates in the platelets from SGK1 deficient mice (Borst et al. 
2012). Besides, the expression of Orai1 protein remarkably decreases in SGK1 
knocked out platelets or inhibitor treated megakaryocytic cell line, although 
STIM1 expression in such cells is not affected. (Borst et al. 2012). Along with this 
line, more regulators of SGK1 signalling are attractive in the regulation of 
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STIM1/Orai1 mediated SOCE, such as NF-κB, IKKβ, IκBα and so on. However, 
the roles of all of them in platelets need more experiments to confirm (Lang et al. 
2015).  
The Akt family protein is another signalling molecule of PI3K signalling, and all 
three isoforms express in platelets (Lang et al. 2015). The absence of Akt1 leads 
to attenuated elevation of [Ca2+]i and platelet aggregation in response to 
thrombin and vWF treatment respectively. (Chen et al. 2004), (Yin et al. 2008). 
Moreover, the Akt also contributes to chemokine CXC motif ligand 16 (CXCL16) 
mediated platelet activation (Borst et al. 2012), and can regulate Orai1 
expression upon PDGF stimulation in human arterial smooth muscle cells 
(Ogawa et al. 2012). However, there was no direct evidence proving that Akt can 
affect the STIM1/Orai1 signalling in platelets. The hypothesis is that it only plays 
a supplement role when SGK1 are absent (Lang et al. 2015). 
Reactive oxygen species (ROSs) generate in platelets upon the stimulation of 
agonists through multiple mechanisms, such as xanthine oxidase and NADPH 
oxidase. (Wachowicz et al. 2002). The ROSs derived from NADPH oxidase not 
only contribute to platelet apoptosis, but also affect platelet activation, 
aggregation and thrombus formation (Girish et al. 2013), (Begonja et al. 2005). 
In addition, [Ca2+]i in ROS-treated human platelets slightly increase via the 
release of agonist-sensitive intracellular stores. But the regulation mechanism of 
ROS is still unclear (Redondo et al. 2004), (Loiko et al. 2003). The ROS 
regulated [Ca2+]i via release of intracellular stores and inhibition of SOCE in 
lymphocytes has been reported by Bogeski. The study also showed that the 
inhibited CRAC channel protein was Orai1, but not Orai3 (Bogeski et al. 2010). 
Further experiments indicated that ROS-regulated inhibition of CRAC channel in 
HEKS1 cells was accomplished by specific sites oxidation of Orai1 protein, 
which reduced the formation of Orai1 cluster (Alansary et al. 2016). However, 
the regulator role of ROSs to platelet STIM1/Orai1 needs further study. 
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1.5 Platelet apoptosis 
Normally, the average life of human platelets in the blood is about 10 days. 
Similar to nucleated cells, senescent platelets can start a process of 
programmed cell death (also called apoptosis), and finally be removed from the 
blood circulation (George 2000). In addition, the stored platelets in vitro, even 
those isolated from healthy human blood, sometimes undergo apoptosis-like 
events, which influence on platelet physiological functions. This is known as 
platelet storage lesion (PSL), which was induced by multiple factors, such as 
storage temperature, storage agitation and so on (Shrivastava 2009), (Mittal and 
Kaur 2015), (Wang et al. 2013). 
The extrinsic factors for platelet apoptosis have been reported in some 
researches. Many kinds of drugs or chemical compounds, such as Vancomycin, 
Thymoquinone and so on, are toxic to human platelets and can induce platelet 
apoptosis in a dose-dependent manner (Towhid et al. 2013) (Towhid et al. 2011). 
Clinically, the use of some drugs may lead to the excessive suicidal death or 
apoptosis of platelets, thus resulting in the significant decrease of platelets in 
circulating blood. This is termed as drug-induced thrombocytopenia (DIT), which 
will result in bleeding disorders (Williamson et al. 2014). Moreover, some 
agonists also induce platelet apoptosis events via interaction with related 
receptors of platelet membrane surface (Li et al. 2010).  
1.5.1 The mechanisms of platelet apoptosis 
Different factors induce platelet apoptosis via different mechanisms. Like the 
nucleated cells, the apoptotic pathways of platelets can also be classified to 
intrinsic and extrinsic pathways (Kile 2014). Generally, the apoptotic process of 
senescent platelets is accomplished through the intrinsic pathway. Kile BT has 
already reviewed and built a molecular model based on previous researches 
(Kile 2009). Briefly, Bcl-2 family proteins make platelets survive by controlling the 
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pro-apoptotic Bak/Bax protein upon the stimulation of apoptotic signalling. For 
example, as an apoptotic signalling, DNA injury can activate the BH3-only 
proteins. The activated BH3-only protein further binds to Bcl-2 family proteins 
and release the Bak/Bax protein at the same time. Bak/Bax complex can form a 
pore in the mitochondrial membrane and discharge cytochrome c (CytC), which 
ultimately lead to caspase-3 activation, phosphatidylserine exposure and platelet 
disassembly (Vogler et al. 2011). 
Although the intrinsic pathway of platelet apoptosis is clear, the extrinsic 
pathway still lacks enough studies. According to previous researches, 
mitochondria might play a key role in platelet apoptosis induced by extrinsic 
stimulation (Gyulkhandanyan et al. 2017). Towhid’s study showed that the 
mitochondrial membrane potential (Δψm) significantly decreased with ceramide 
formation upon the thymoquinone treatment in human platelets, which activate 
the caspase cascades and lead to platelet apoptosis. Concomitantly, [Ca2+]i also 
increase significantly, which could be induced by thymoquinone via PI3k/Akt 
signalling pathway (Towhid et al. 2011). High level of [Ca2+]i can directly lead to 
Δψm loss by opening the mitochondria permeability transition pore (MPTP) 
(Sveshnikova et al. 2015). Δψm. loss might also be caused by the binding of high 
level of [Ca2+]I to potential mediator calpain, which can induce platelet apoptosis 
in Ca2+-dependent manner (Zhang et al. 2011). In addition, ROS, like hydrogen 
peroxide (H2O2), can regulate SOCE and [Ca
2+]i (Rosado et al. 2004), the 
release of cytochrome c, as well as the activation of caspase-3 (Lopez et al. 
2007). Besides, further experiments show that ROS treatment can also lead to 
the activation of Bid and Bax, thus resulting in platelet apoptotic (Fig.1.3) (Lopez 
et al. 2008). 
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Fig.1.3. General mechanism of platelet apoptosis (Thushara et al. 2015) 
1.5.2 Agonists-induced platelet apoptosis 
As is described earlier, platelets perform the hemostatic function depending on 
the stimulation of agonists. Yet many kinds of agonists can also induce platelet 
apoptotic events according to the reports (Leytin 2012). 
Low concentration of thrombin evokes high level expression of platelet 
P-selectin in vitro. However, thrombin-induced caspase-3 expression of platelets, 
PS exposure and Δψm loss were in a dose-dependent manner (Leytin et al. 
2007). Furthermore, ROS play an important role in thrombin-induced platelet 
apoptotic events, because they can directly or indirectly trigger Δψm loss, thus 
leading to the activation of caspase cascades (Lopez et al. 2007). Carrim’s 
research showed that thrombin mediated ROS production was through its 
binding to protease-activated receptor 4 (PAR4), but not PAR1. At the same time, 
GPIbα also contributed to this process. GPIbα/PAR4 together activated 
downstream effector protein FAK and NOX1, thus inducing ROS formation 
(Carrim et al. 2015). In addition, thrombin triggered platelet apoptotic events in 
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vitro were also associated with the temperature and time of treatment. Besides, 
it could selectively cause platelet activation or apoptosis by different 
mechanisms under different conditions (Gyulkhandanyan et al. 2013). 
Like thrombin, collagen, another potent agonist, can also induce platelet 
apoptotic events. Although the Δψm only changes slightly, the caspase-3 and 
caspase-9 increase significantly following the treatment of collagen (Lin et al. 
2009). Moreover, some weak agonists, such as ADP and U46619, can also 
cause apoptosis events in human platelets (Tonon et al. 2002). 
1.5.3 Apoptotic markers of anucleate platelets  
Similar to nucleated cells, the apoptosis of anucleate platelets exhibit a variety of 
characteristics in protein level and morphological change. The detection 
methods and applications of these characteristics have been reviewed by 
Gyulkhandanyan et al (Gyulkhandanyan et al. 2012). Depolarization of Δψm is 
considered as one of the important characteristics of platelet apoptosis induced 
by both intrinsic and extrinsic pathways (Jackson and Schoenwaelder 2010). In 
addition, PS exposure is a key characteristic of the nucleated cells apoptosis. 
However, PS exposure is increased during both platelet activation and apoptosis, 
which could be induced by different mechanisms (Kile 2014), (Arachiche et al. 
2009). Moreover, platelet apoptosis can lead to morphological changes, such as 
cell shrinkage, blebbing, shedding of microparticles and so on (Leytin et al. 
2004). 
1.5.4 The effects of PS exposure on platelets 
PS is one of the phospholipids in plasma membranes of most mammalian cells. 
Normally, they are located in the inner leaflet of the phospholipid bilayer, and 
form an asymmetric distribution with other phospholipids, such as 
phosphatidylcholine and sphingomyelin (Zwaal 1978). The asymmetry of 
membrane phospholipids depends on the regulation of flippases, floppases and 
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scramblases (Hankins et al. 2015). Upon the stimulation of apoptotic signalling, 
large quantities of PS are transported from inner leaflet to outer leaflet. Afterward, 
exposed PS can bind to PS receptor Tim4 of macrophages surface, which can 
clear the senescent platelets with the combined action of various proteins, such 
as MFG-E8, Gas6 and protein S (Toda et al. 2012), (Dransfield et al. 2015). Xkr8 
plays a key role in caspase-related PS exposure during FasL-induced nucleated 
apoptosis (Suzuki et al. 2013). It can be activated by caspase-3 cleavage, and 
execute phospholipid scrambling by forming a complex with basigin (BSG) or 
neuroplastin (NPTN) (Suzuki et al. 2016). 
The PS exposure of platelets also contributes to blood coagulation (Lentz 2003). 
As is described above, some coagulation factors, such as FVII, FIX and FII, can 
assemble with some protein cofactors and form a complex at the surface of 
phospholipid membrane during blood coagulation. This is accomplished by the 
binding of PS to N-terminal γ-carboxyglutamic acid (Gla) residues of these 
Vitamin K-dependent enzymes only, which can only take place when Ca2+ exist. 
(Ohkubo and Tajkhorshid 2008). However, some proteins, such as 
nonenzymatic cofactors FVIIIa and FVa, require the attendance of PS rather 
than Ca2+ to bind to the plasma membrane. They may bind to phospholipid of 
plasma membrane via C2 domain (Ngo et al. 2008). 
1.6 Anoctamin 6 (Ano 6)  
1.6.1 Anoctamin protein family 
Anoctamin (Ano, also known as Tmem16) protein family was first identified and 
characterized through sequence analysis by Katoh et al. in 2004 (Katoh 2004a). 
It contains 10 members in mammalian cells, which are termed from Ano 1 
(Tmem16A) to Ano 10 (Tmem16K) successively (Duran and Hartzell 2011). All 
Anoctamin family proteins contain a 8- transmembrane domains, and C- and N- 
termini that insert into cytosol (Pedemonte and Galietta 2014). In addition, the 
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first two members of Anoctamin family were reported respectively as the typical 
Ca2+-activated Cl- channel (CaCC) in 2008 by three different laboratories 
(Caputo et al. 2008), (Yang et al. 2008), (Schroeder et al. 2008). Further studies 
show that the physiological role of each member is different, yet none is 
completely clear until now. 
1.6.2 Defective Ano 6 underlies the Scott syndrome 
The Scott syndrome was reported many years ago as a rare inherited bleeding 
disorder (Weiss et al. 1979), (Satta et al. 1997). The platelets from Scott patients 
display defective Ca2+ -dependent PS exposure, which further results in low 
consumption of serum prothrombin and thus decreased generation of thrombin 
(Lhermusier et al. 2011). As is described above, the platelet PS exposure is 
regulated by scramblase. This mechanism in Scott platelets remains obscure, 
though early studies showed that the platelets from Scott patients displayed 
strong scrambling of membrane phospholipids upon agonists stimulation. 
(Rosing et al. 1985). 
According to Suzuki’s report, the knock down of Ano 6 (Tmem16F) significantly 
decreased Ca2+ -dependent PS exposure in Ba/F3 cell line (Suzuki et al. 2010). 
Later on, Yang and his colleagues further reported that compared with wild type 
mice, Ano 6 knockout mice exhibited prolonged bleeding, reduced thrombin 
production in PRP, and decreased PS exposure (Yang et al. 2012). All of these 
phenomena were analogous to the characteristics of Scott syndrome. Moreover, 
two novel mutation sites were found in the Tmem16F gene through the 
sequence analysis of the platelet DNA from a Scott patient (Castoldi et al. 2011). 
Recently, different mutation sites of Tmem16F gene were reported in another 
two Scott patients (Boisseau et al. 2016). These reports indicate that Ano 6 
involves in platelet scramblase activity and is strongly associated with Scott 
syndrome.  
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1.6.3 The effect of Ano 6 on platelets 
Yang et al reported that Ano 6 was a Ca2+ dependent cation channel with Ca2+ 
permeability, which regulated thrombin generation and procoagulant activity 
through its regulation of platelet lipid scrambling. (Yang et al. 2012). When 
treated with thrombin/collagen, Scott platelets exhibited reduced PS exposure 
and Δψm depolarization compared with normal platelets. However, in both the 
Soctt platelets and control groups, [Ca2+]i increased similarly with the agonists 
stimulation (van Kruchten et al. 2013). Moreover, upon the treatment of A23187, 
platelets from Tmem16Ffl/fl;Pf4-CRE mice, a platelet-specific Ano 6 deficient 
mice, displayed  suppressed microparticle shedding in vitro; upon the treatment 
of laser, they showed decreased thrombus formation in vivo. (Fujii et al. 2015). 
According to Baig’s report, the platelets from conditional Ano 6 knockout mice 
also exhibited prolonged bleeding and fibrin formation (Baig et al. 2016).  
Despite the aforementioned reports on the effect of Ano 6 on platelets, the role of 
Ano 6 in platelets remains less known. Therefore, this study further explores 
whether Ano 6 participates in the regulation of platelet [Ca2+]i, oxidative stress, 
activation and agonists induced apoptosis by using a Ano 6 deficient mice 
model.  
1.7 γ-secretase and DAPT 
γ-secretase, a member of intramembrane-cleaving proteases (i-CLiPs) family, 
consist of nicastrin, presenilin, anterior pharynx defective 1 and presenilin 
enhancer 2 (Sun et al. 2015). Presenilin, divided into presenilin-1 and 
presenilin-2, are indispensable among all the components and play a crucial role 
in catalyzing the hydrolysis of substrate (Kimberly et al. 2003). Most of the 
currently identified genetic mutations causing Alzheimer’s disease (AD) occur in 
the genes encoding presenilin-1 protein (De Strooper et al. 2012). In platelets, 
presenilin-1 are extensively expressed as the catalytic subunits of γ-secretase 
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and mainly located in the membrane of α-granules (Mirinics et al. 2002). 
DAPT, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, 
potently inhibit activity of γ-secretase complex as a specific inhibitor through 
binding with C-terminal fragment of presenilin (Fig.1.4) (Morohashi et al. 2006). 
DAPT was wildly used in the related researches of functions and signaling of 
γ-secretase and its target proteins, such as Notch, CD44 and APP 
(Androutsellis-Theotokis et al. 2006), (Roberts et al. 2017), (Johansson et al. 
2017). 
 
Fig.1.4 Chemical structure of γ-secretase inhibitor DAPT  
(Sigma-Aldrich PubChem Substance ID 24893987) 
1.7.1 The functions of γ-secretase 
It was reported that γ-secretase and the related components can perform 
proteolytic and non-proteolytic functions in different cells (Zhang et al. 2014). 
First of all, as an i-CLiPs, γ-secretase mainly catalyze and cleave type I 
membrane proteins, such as amyloid precursor protein (APP), CD44, Notch-1–4 
and so on (Kopan and Ilagan 2004). APP is firstly cleaved by β-secretase. Then 
carboxyl-terminal fragments of APP (APP-βCTF or C99) are further cleaved by 
γ-secretase to successively produce amyloid-β (Aβ) peptide of different lengths 
(Haass et al. 2012). It is well known that the mass aggregation of Aβ in brain 
results in AD. Besides, platelets expressed a variety of isoforms of APP and 
released Aβ upon agonists stimulation (Evin and Li 2012). Gowert et al. reported 
that at different concentrations, Aβ could enhance the ADP-induced platelet 
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activation, and also cause PS exposure, ROS generation and caspase-3 
activation (Gowert et al. 2014).  
Secondly, the non-proteolytic role of γ-secretase and the related components 
have attracted some attention. In rat neurons, the expression of mutated 
presenilin-1 not only inhibited γ-secretase activity, but also displayed prolonged 
SOCE upon the stimulation of cyclopiazonic acid. Further experiments showed 
that the γ-secretase inhibitor treated neurons also displayed slightly prolonged 
SOCE (Shideman et al. 2009). The death of B103 cells, induced by A23187 in 
Ca2+-dependent manner, significantly reduces following its co-incubation with 
γ-secretase inhibitors. However, these inhibitors cannot block the effect of 
staurosporin, which induce the apoptosis of B103 cells in a caspase-dependent 
manner (Choi et al. 2010). 
1.7.2 The proteolysis of CD44 depend on γ-secretase activity 
CD44, a multifunctional transmembrane glycoprotein and (co)receptor widely 
expressed in many cells, contribute to the regulation of cell migration, growth, 
wound healing and so on (Liu et al. 2016). Similar to APP, they were also 
cleaved by γ-secretase to generate and release two fragments- intracellular 
domain (CD44-ICD) and soluble CD44 (Fig.1.5) (Nagano and Saya 2004). The 
former translocated to nucleus and regulated the transcription of target genes 
(including CD44 itself) through binding to TPA-responsive elements (Okamoto et 
al. 2001). The ectodomain cleavage of CD44 involved in the regulation of cell 
migration (Sugahara et al. 2003). 
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Fig.1.5. Proteolytic processes of CD44 (Nagano and Saya 2004) 
The impact of CD44 on platelet activation and apoptosis has been reported 
utilizing a CD44 deficient mice model (Liu et al. 2016). Compared with wild type 
mice, the platelets from CD44 deficient mice displayed enhanced activation, PS 
exposure and caspase-3 activity after treatment with the agonists in vitro. The 
SOCE of CD44 deficient platelets significantly elevated in comparison with wild 
type mice. Similarly, thrombus formation of CD44 deficient mice in vitro also 
significantly increased under the high arterial shear rates. 
All these reports point to the potential role of γ-secretase in platelets. Therefore, 
this study explored whether γ-secretase inhibitor DAPT regulated platelet Ca2+ 
signaling and SOCE as well as DAPT modified the stimulating effect of CRP on 
platelet activation, apoptosis and oxidative stress. 
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2. Materials and Methods 
2.1 Preparation of mice 
The generation of Ano 6 deficient mice (ano6-/-) and corresponding wild type 
mice (ano6+/+) has been described detailed elsewhere (Ehlen et al. 2013), and 
littermates mice were genotyped utilizing polymerase chain reaction (PCR). 
Wild type C57BL/6 mice were provided for γ-secretase relative experiments. 
Before taking blood from the mice, free drinking water and the control of chow 
were necessary (Ssniff, Soest, Germany). All animal experiments were 
conducted in line with the animal welfare law of Germanym and were approved 
by the authorities of the state of Baden-Württemberg. 
2.2 Isolation of platelets 
Platelets were isolated from the whole blood of 3 month-old mice of either sex. 
The mice were rapidly anesthetized before 800 µl blood was taken from each 
mouse and put into a 1.5 ml tube containing 200 µl acid-citrate-dextrose buffer 
(ACD, 80 mM citrate, 50 mM citric acid, 180 mM D-gluclose). 200 µl Tyrode 
buffer (pH 7.4, 133 mM NaCl, 12 mM NaHCO3, 10 mM HEPES, 2.8 mM KCl, 5 
mM D-glucose, 0.1% Bovine serum albumin) without Ca2+  was added into 
ACD-blood. Then the mixture was centrifuged at 260 g for 5 minutes to obtain 
platelet rich plasma (PRP). Next, PRP was transferred to another 1.5 ml tube 
and the platelets were pelleted after a 640 g centrifugation for 5 minutes. 
During this process, 0.02 U/ml apyrase (Sigma-Aldrich) and 0.5 µM 
prostaglandin I2 (Calbiochem) were added to prevent the activation of platelets. 
Then the platelet pellet was washed twice before it was resuspended in 200 µl 
Tyrode buffer. The concentration of washed platelets was measured utilizing 
KX21-N automatic hematology analyzer (Sysmex). 
In order to test blood parameter, 100 µl fresh EDTA-anticoagulated whole 
blood was obtained from Ano 6 defective mice and corresponding wild type 
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mice. Blood count was performed utilizing automatic hematology analyzer. 
2.3 The impact of defective Ano 6 on platelet activation and 
apoptosis  
2.3.1 Quantification of ROS  
2’,7’- Dichlorofluorescin diacetate (DCFDA, Sigma-Aldrich, Schnelldorf, 
Germany) was used to determine platelet oxidative stress. 108 isolated ano6-/- 
and ano6+/+ platelets were stimulated by 0.01 U/ml thrombin (Roche, 
Switzerland) and 2 µg/ml collagen related peptide (CRP, provided by R. 
Farndale, University of Cambridge, Cambridge, UK) in the presence of 1 mM 
CaCl2 and then incubated for 15 minutes at 37°C. The platelets of control 
groups were treated with Tyrode buffer in the same conditions. All the samples 
were washed twice with the 300 µl Tyrode buffer after agonist stimulation. Next, 
the treated platelets were stained for 30 minutes in 50 µl buffer containing 10 
µM DCFDA, and the loaded platelets were washed once to remove residual 
dye. After a 760 g centrifugation, samples were resuspended in 200 µl Tyrode 
buffer and then ROS related fluorescence was measured by Fluorescence 
activated cell sorting (FACS, Calibur) system (BD, Heidelberg, Germany). 
DCFDA fluorescence was detected at an excitation wavelength of 488 nm and 
an emission wavelength of 530 nm (FL1 channel) on FACS machine. 
2.3.2 Agonists-induced platelet Ca2+ response 
For the measurement of [Ca2+]i, platelet pellet was resuspended in 100 µl 
Tyrode buffer without CaCl2 , and 10
6 platelets were transferred into a 1.5 ml 
tube. All the samples were stained with 3 µM Fluo-3 (Biotinium, USA) and then 
incubated at 37°C for 30 minutes. The samples were washed once and 
resuspended in 100 µl Tyrode buffer (1 mM CaCl2). After stimulation with 0.01 
U/ml thrombin or 2 µg/ml CRP for 100 seconds, activated Fluo-3 fluorescence 
was detected immediately in FL1 channel of FACS machine (excitation 
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wavelength: 488 nm, emission wavelength: 530 nm). 
2.3.3 Platelet store-operated calcium entry (SOCE)  
Platelets were firstly resuspended in 100 µl Ca2+ free Tyrode buffer and the 
final concentration was adjusted to 106 platelets/ml. Afterwards, platelets were 
treated with 3 µM Fluo-3 (Biotinium, USA) for 30 minutes at 37°C. Then the 
samples were washed for another time, and the loaded platelets were again 
suspended in Ca2+ free Tyrode buffer containing 1 µM thapsigargin 
(Invitrogen). After 10 minutes incubation, Ca2+ store depletion was measured 
immediately in FL1 channel of BD FACS. In order to measure store-operated 
Ca2+ entry, 1 mM CaCl2 was added into the thapsigargin treated sample. 5 
minutes later, the fluorescence of sample was detected utilizing FACS. 
2.3.4 Orai1 protein abundance at the platelet surface 
The expression of Orai1 protein at the surface of platelets was measured 
utilizing fluorescent labeled antibody and flow cytomerty. 108 platelets were 
stimulated by 0.01 U/ml thrombin and 2 µg/ml CRP in 100 µl Tyrode buffer 
containing 1 mM CaCl2. 15 minutes later, 200 µl Tyrode buffer were added into 
the samples, which was followed by 760g centrifugation for 5 minutes. Washed 
platelets were fixed with 1% paraformaldehyde for 10 minutes. Next, all the 
samples were washed once and incubated with anti-Orai1 primary antibody 
(ab59330, Abcam; rabbit anti-mouse antibody) for 90 minutes at 37oC. 
Following another time of wash, the treated platelets were further incubated 
with 1:250 diluted anti-rabbit secondary antibody (CF™ 488A; Sigma, USA) for 
1 hour. Labeled platelets were analyzed immediately in FACS Calibur (FL1). 
2.3.5 Expression of total Orai1 protein in platelets 
Immunofluorescence and confocal laser scanning microscopy were used to 
determine the expression of total Orai1 protein in platelets. 3×106 platelets 
were adhered to fibrinogen coated surface on glass slips and fixed with 200 µl 
1% paraformaldehyde (PFA) for 15 minutes. Following two times of wash, the 
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platelets were blocked for 20 minutes by 200 µl Tyrode buffer containing 2% 
BSA. Platelet membrane was permeabilized by 0.1% Triton-X 100 treatment 
for 5 minutes and then washed once to remove residual reagent. After that, the 
platelets were incubated with anti-Orai1 primary antibody (1:200, Abcam) 
overnight at 4oC. The slips were washed twice and the platelets were 
incubated with secondary antibody (1:200; CF™ 488A, Sigma) for 2 hours in 
darkness. Additional F-actin was stained with rhodamine-phalloidin (1:200; 
Invitrogen) for 30 minutes at the room temperature. Then the samples were 
mounted with ProLong Gold antifade reagent (Invitrogen), and fluorescent 
pictures from 63× ocular were taken utilizing confocal laser scanning 
microscope (Zeiss LSM 5 EXCITER; Carl Zeiss, Germany). 
2.3.6 P-selectin abundance and integrin αIIbβ3 activation 
Platelet activation was measured utilizing both FITC conjugated P- selectin 
antibody (Wug.E9-FITC) and PE conjugated integrin αIIbβ3 (JON/A-PE) 
antibody. 106 platelets from ano6-/- and ano6+/+ mice were suspended in 50 µl 
Tyrode buffer with CaCl2 (1 mM). All the samples were incubated with 
fluorophore labeled antibodies (1:10 dilution) and then stimulated with 0.01 
U/ml thrombin or 2 µg/ml CRP at 37°C. 15 minutes later, 150 µl PBS were 
added into the sample to stop the reaction. Two-color staining was analyzed 
immediately on FACS machine following fluorescent compensation setting. 
2.3.7 Phosphatidylserine exposure and forward scatter 
In order to evaluate the effect of Ano 6 on Ca2+ dependent PS exposure, 
platelets were centrifuged at 640g for 5 minutes, and then the platelet pellet 
was resuspended in 100 µl modified Tyrode buffer (1 mM Ca2+). Next, the 
samples were treated with 0.01 U/ml thrombin or 5 µg/ml CRP at 37°C for 15 
minutes, and then 200 µl Tyrode buffer was added to the sample to stop the 
reaction. Then the samples were washed once before they were stained with 
1:20 dilution of Annexin-V FITC (Mabtag, Germany) in 50µl Tyrode buffer 
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containing 2 mM CaCl2. Treated platelets were moved to the incubator and 
incubated for 20 minutes at 37oC. The volume of sample was supplemented to 
200 µl with Tyrode buffer and fluorescent analysis was performed immediately 
in FL1 channel of BD FACS. At the same time, platelet size was analyzed by 
forward scatter (FSC). 
2.3.8 Platelet aggregation 
Agonist induced platelet aggregation was measured utilizing FACS machine as 
previously reported (De Cuyper et al. 2013). Platelets, with the concentration 
no less than 5 × 107 platelets/ml, were pre-incubated respectively with 
CD9-APC and CD9-PE antibodies (Abcam; 1:100 dilution) in Ca2+ free Tyrode 
buffer at the room temperature. After 15 minutes, the samples were washed 
twice to remove residual antibody, and then the platelet pellet was 
resuspended in 100 µl modified Tyrode buffer with 1 mM CaCl2. The differently 
labeled platelets of each group were mixed in 1:1 ratio, and then the mixture 
was incubated at 37oC while being shaken at 600 rpm for 10 minutes. Next, 
the platelets were stimulated with CRP or thrombin under the condition of 
shaking (1000 rpm). At the indicated time points (0, 2, 4, 6, 8, 10 minutes), 
labeled-platelets were immediately fixed by 0.5% paraformaldehyde (Carl Roth, 
Germany) in PBS buffer, and then the samples were analyzed by flow 
cytometry in FL2 and FL4 channel.  
The percentage of double-colored events against total labeled events was 
used to evaluate platelet aggregation. A quadrant was first set in dot plot 
model of FL2 and FL4 channels using labeled-resting platelets. 
Double-colored events appeared in upper right quadrant (Q2) following 
agonists simulation and the sum of events in the three regions (Q1+Q2+Q4) 
represents the total labeled events. 
2.4 Effect of γ-secretase inhibitor DAPT on platelet activation 
and apoptosis 
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2.4.1 CRP-induced platelet Ca2+ response  
To explore the effect of γ-secretase inhibitor DAPT upon CRP stimulation on 
[Ca2+]i, the platelets were exposed to 10 µM DAPT while being stained with 
Fluo-3 (3µM) in Ca2+ free Tyrode buffer for 30 minutes. After a wash, the 
loaded platelets were suspended in 100 µl Tyrode buffer with 1mM CaCl2. 
Then the samples were stimulated with the agonist in two different ways. The 
first was to stimulate the platelets with CRP of different concentrations (0.5, 1, 
2, and 5 µg/ml) for 100 seconds. In the second way, both the control and 
DAPT treated platelets were treated with 2 µg/ml CRP for different time 
durations (50, 100, 150 and 200 seconds). The fluorescence of sample was 
measured on FACS machine (FL1 channel). 
2.4.2 DAPT sensitive platelet SOCE 
106 platelets were suspended in Ca2+ free Tyrode buffer and stained with 3 µM 
Fluo-3 for 30 minutes in the presence of γ-secretase inhibitor DAPT (10 µM). 
Following a wash, the loaded platelets were resuspended into 100 µl Ca2+ free 
Tyrode buffer and treated with1 µM thapsigargin for 10 minutes. Platelet Ca2+ 
store depletion was detected immediately by flow cytometry in the absence of 
extracellular Ca2+. 1 mM CaCl2 was added into the thapsigargin treated sample 
to trigger platelet SOCE. After 5 minutes of incubation, the fluorescence of 
sample was detected utilizing FACS. 
2.4.3 The analysis of Orai1/STIM1 protein expression using Western blot 
Following CRP stimulation, DAPT treated platelets were collected by 
centrifugation at 1000 rpm for 3 minutes. Then the pellet was resuspended in 
100 µl cell lysis buffer (1:10; cell signaling, #9803) containing EDTA-free 
protease inhibitor cocktail (cOmplete™, Sigma-Aldrich). After a 10 minutes 
centrifugation at 14000g and 4°C, the supernatant was moved into a 1.5 ml 
cooled centrifuge tube and then protein concentration was measured utilizing 
Bradford (Bio-Rad). Afterwards, platelet proteins were separated and 
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transferred to PVDF membrane by SDS- polyacrylamide gel electrophoresis. 
The membrane was blocked with 5% BSA for 60 minutes at room temperature. 
Following two washes, it was incubated with the primary antibody against 
Orai1(0.5 µg/ml, Abcam), STIM1(1:1000, Cell Signaling) and GAPDH (1:1000, 
Cell Signaling) overnight at 4°C. Next, the membrane was washed three times 
with TBS-T buffer, and then incubated with horse radish peroxidase (HRP) 
conjugated secondary antibody (1:5000, Cell Signaling) for 60 minutes at room 
temperature. Antibody binding was detected utilizing the Hyperfilm ECL 
detection system (Amersham, GE healthcare), and the optical density of the 
bands was quantified by scanning densitometry. 
2.4.4 Orai1protein abundance at the platelet surface  
The expression of Orai1 protein at the surface of platelet plasma membrane 
was measured using flow cytometry. The platelets were treated with two ways. 
In one way, 106 isolated platelets were pretreated with γ-secretase inhibitor 
DAPT (Sigma-Aldrich, Germany) of the indicated concentration (1, 5, 10, 20 
µM) at 37oC for 30 minutes. Pretreated-platelets were washed once and 
stimulated with 2 µg/ml CRP for 100 seconds in 100 µl Tyrode buffer (1mM 
CaCl2). In the second way, platelets were pretreated with 10 µM DAPT for 30 
minutes and then stimulated with 2 µg/ml CRP (100 seconds, 15 minutes). 
Next, activated-platelets were fixed with 1% paraformaldehyde for 10 minutes. 
After one wash with Tyrode buffer, all the samples were incubated with primary 
anti-Orai1 antibody (ab59330, Abcam; rabbit anti-mouse antibody) for 90 
minutes at 37oC. Afterwards, the samples were washed again and then 
incubated with anti-rabbit secondary antibody in 1:250 diluted (Sigma, USA) 
for 1 hour, which was labeled by CF™ 488A. Antibody related fluorescence 
was analyzed immediately on FACS Calibur. 
2.4.5 Platelet degranulation and integrin αIIbβ3 activation 
Platelet P-selectin and integrin αIIbβ3 abundance were measured respectively 
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utilizing their corresponding fluorophore conjugated antibodies. After a 10 µM 
DAPT treatment for 30 minutes, 106 platelets were incubated with antibodies of 
P-selectin (Wug.E9-FITC) and αIIbβ3 integrin (JON/A-PE) in the presence of 2 
µg/ml CRP. Following 15 minutes stimulation, 150 µl PBS were added into the 
samples to stop the reaction. Two-color analysis was performed using BD 
FACS machine.  
2.4.6 Reactive oxygen species (ROS) formation 
Platelets were first treated with 10 µM γ-secretase inhibitor DAPT at 37oC for 
30 minutes. After one wash, both control and DAPT treated-platelets were 
resuspended in 200 µl Tyrode buffer with 1 mM CaCl2 and loaded with 10 µM 
2’,7’- dichlorodihydrofluorescein diacetate (DCFDA; Sigma-Aldrich) for 30 
minutes. Next, the loaded platelets were stimulated by 2 µg/ml CRP and the 
ROS relative fluorescence was measured at the interval of one minute within 
15 minutes. 
2.4.7 Mitochondrial membrane potential 
The loss of platelet mitochondrial membrane potential was evaluated using 
flow cytometry. The isolated platelets were first incubated with 10 µM DAPT for 
30 minutes as is described above. 108 treated platelets were further stimulated 
with 5µg/ml CRP for 60 minutes and stained for 30 minutes with 10 μM TMRE 
(tetramethylrhodamine, ethyl ester perchlorate; Invitrogen, USA) in the dark. 
The fluorescence of TMRE loaded platelets were determined utilizing FL1 
channel of FACS machine. 
2.4.8 Platelet PS exposure and cell shrinkage 
In order to evaluate the effect of γ-secretase inhibitor DAPT on platelet PS 
exposure, 108 platelets were first incubated for 30 minutes with 10 µM 
γ-secretase inhibitor DAPT and then stimulated with 5 µg/ml CRP for 10 
minutes in the presence of 1 mM CaCl2. Afterwards, 200 µl Tyrode buffer were 
added into the samples to stop the reaction. Following a wash, the platelets 
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were stained with 1:20 dilution of Annexin-V FITC (Mabtag, Germany) in 50 µl 
Tyrode buffer with 2 mM CaCl2. After 20 minutes incubation, Annexin-V binding 
that reflected PS exposure at the platelet surface was analyzed on FACS 
machine (FL1 channel). At the same time, platelet shrinkage was analyzed 
utilizing forward scatter (FSC) of dot plot model.  
2.4.9 DAPT sensitive platelet aggregation 
DAPT sensitive platelet aggregation was tested utilizing flow cytometry as is 
aforementioned. To this end, platelets were labeled with 1:100 diluted 
CD9-APC (Abcam, ab82392; Ex: 645nm, Em: 660nm), while equal amounts of 
platelets were labeled with CD9-PE antibodies (Abcam, ab82394; Ex: 488nm, 
Em: 575nm) for 15 minutes. After two times of wash, the two differently labeled 
platelets were mixed in the ration of 1:1. The mixture was treated with 10 µM 
DAPT (Sigma-Aldrich, Germany) for 30 minutes and shaken at low frequency 
(600 rpm) for 10 minutes. Then, the samples were treated with CRP (2 ug/ml) 
while being shaken at the frequency of 1000 rpm. Following their fixation with 
0.5% paraformaldehyde in PBS, the samples were analyzed using flow 
cytometry. The percentage of double-colored events against the total 
fluorescent events was used to evaluate platelet aggregation. 
2.4.10 In vitro platelet thrombus formation  
Glass coverslips were coated with 250 μl Tyrode buffer containing 100µg/ml 
collagen overnight at 4°C. Whole blood was taken with heparin anticoagulant 
and then diluted 1:3 with Tyrode buffer (pH 7.4, 2 mM CaCl2). After that, the 
sample was perfused with high shear rates (1700 s-1) through a transparent 
parallel-plate flow chamber (slit depth 50 µm) over a collagen coated glass 
coverslip for 5 minutes. Next, the flow chamber was rinsed with Tyrode buffer 
for 5 minutes utilizing peristaltic pump. Images of platelet adhesion were 
captured from 4 or 6 different microscopic fields of CCD camera (Axiovert 200, 
objective 20x; Carl Zeiss, Germany). The image analysis was performed 
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utilizing AxioVision software (Carl Zeiss) and the mean value of the covered 
area was calculated to estimate thrombus formation in vitro.  
2.5 Statistical analysis  
The statistical analysis of collected-data was performed via one-way ANOVA 
with Tukey’s test using Graphpad Prism 6.1 software, which applies to 
post-test and unpaired- student’s t-test. All the results were reported as 
arithmetic means value ± SEM (standard error of mean) using Microsoft excel 
2010, while n represents the repeated number of independent experiments. 
The results were considered statistically significant with P-value <0.05. 
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3. Results 
The parts of results in this dissertation have been published as follows: 
Liu G, Liu Guilai, Chatterjee M, Umbach A.T, Chen H, Gawaz M, Lang F. Influence of 
γ-Secretase Inhibitor 24-Diamino-5-Phenylthiazole DAPT on Platelet Activation. Cell Physiol 
Biochem. 2016;38(2):726-36. 
Liu G, Liu Guilai, Chen H, Borst O, Gawaz M, Vortkamp A, Schreiber R, Kunzelmann K, 
Lang F. Involvement of Ca
2+
 Activated Cl
-
 Channel Ano 6 in Platelet Activation and 
Apoptosis. Cell Physiol Biochem. 2015;37(5): 1934-44. 
3.1 The role of Ano 6 on platelet activation and apoptosis 
This study explored whether Ano 6 affects physiological parameter of platelets in 
the blood. For this goal, Whole blood was taken from Ano 6 deficient mice 
(ano6-/-) and corresponding littermates wild type mice (ano6+/+). As is listed in 
Table 3.1.1, Platelet number in the blood of ano6-/- mice was significantly higher 
(p<0.05) in comparison with wild-type mice. Moreover, the data showed that 
others platelet parameters of ano6-/- mice such as platelet volume, platelet 
distribution width and platelet larger cell ratio were similar to that of ano6+/+ mice. 
Besides, the physiological parameters of erythrocyte including number, 
hemoglobin concentration, volume, and so on were also investigated in this 
research, and all of them were actually identical in Ano 6 deficient mice and wild 
type mice. 
 
Table 3.1.1: Blood parameter of ano6
-/-
 mice and corresponding ano6
+/+
 mice. 
Arithmetic mean (AM) ± SEM (n = 6~9), *(p<0.05) shows significant difference between the 
two genotypic mice (Liu et al. 2015). 
 
 ano6
+/+
 ano6
-/-
 
Platelet number (10
3
/µl) 1086 ± 53.58  1252 ± 39.59* 
Mean platelet volume (MPV) (fl) 6.40 ± 0.11 6.27 ± 0.10 
Platelet Distribution Width (PDW) (fl) 7.33 ± 0.17 7.11 ± 0.17 
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Platelet larger cell ratio (P-LCR) (%) 4.68 ± 0.51 4.21 ± 0.48 
Erythrocyte number (10
6
/µl) 11.25 ± 2.11 10.56 ± 1.35 
Hemoglobin (g/dl) 13.90 ± 0.45 14.34 ± 0.33 
Hematocrit (%) 44.35 ± 1.12 46.33 ± 0.97 
Mean erythrocyte volume (MCV) (fl) 51.13 ± 0.25 50.99 ± 0.41 
Erythrocyte hemoglobin concentration 
(MCHC) (g/dl) 
31.25 ± 0.33 32.07 ± 0.97 
Hemoglobin/erythrocyte (MCH) (pg) 15.98 ± 0.23 15.80 ± 0.26 
 
In order to test the impact of Ano 6 with agonists stimulation on platelet [Ca2+]i, 
Fluo-3 was employed to measure cytosolic Ca2+ activity. As is illustrated in 
Fig.3.1.1, resting platelets displayed similar [Ca2+]i in ano6
+/+ platelets and ano6-/- 
platelets (Fig.3.1.1A, D). Following stimulation of 0.01 U/ml thrombin for 100 
seconds, [Ca2+]i significantly (p<0.001) increased in both ano6
+/+ and ano6-/- 
platelets. However, the increased magnitude of [Ca2+]i  was significantly (p<0.05) 
less pronounced in Ano 6 deficient platelets in comparison with normal platelets 
(Fig.3.1.1B, D). Activation of the platelets with 2 µg/ml CRP treatment for 100 
seconds was followed by a significant (p<0.001) increase of [Ca2+]i in both Ano 6 
deficient and wild type platelets. The effect of CRP and thrombin, however, was 
remarkably smaller in platelets from Ano 6 deficient mice than in platelets from 
wild type mice (Fig.3.1.1C, D). 
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Fig.3.1.1. Ano 6 sensitive agonists induced platelet Ca
2+
 response  
A-C. Typical histogram of platelet Fluo-3 fluorescence from FACS assay indicated cytosolic 
Ca
2+
 activity before (A) and after a 100 sec exposure to (B) thrombin (0.01 U/ml) or (C) CRP 
(2 µg/ml). Grey shadows: ano6
+/+
 platelets, black lines: ano6
-/-
 platelets. 
D. Arithmetic mean (AM) ± SEM (n = 4) of fluorescence intensity (arb-units) of Fluo-3 in 
ano6
+/+
 platelets (white bars) and ano6
-/- 
platelets (black bars).  
###(p<0.001) represents significant increase from the stimulation of thrombin or CRP, 
*(p<0.05) represents significant decrease from defective Ano 6. (Liu et al. 2015) 
It is known that the depletion of intracellular Ca2+ pool causes extracellular Ca2+ 
entry via store-operated Ca2+ channel in platelets. In order to explore the effect 
of Ano 6 on platelet SOCE, Thapsigargin, sarco/endoplasmic reticulum Ca2+ 
ATPase inhibitor, was used to treat the platelets form Ano 6 deficient mice and 
corresponding wild type mice. As is illustrated in Fig.3.1.2A, [Ca2+]i of ano6
+/+  
and ano6-/- platelets increased remarkably  with 1 µM thapsigargin treatment for 
10 minutes in the absence of extracellular Ca2+, and the effect of Ano 6 was 
negligible. After the addition of 1 mM CaCl2, platelet [Ca
2+]i further elevated, but 
there was no significant difference between the two genotypes. 
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Agonists induced an impaired Ca2+ response in ano6-/- platelets. In order to 
elucidate whether Orai1 channel contributed to this process, the expression of 
Orai1 protein was measured utilizing flow cytometry and immunofluorescence. 
As is demonstrated in Fig.3.1.2B, the expression of Orai1 was similarly low at 
the surface of the resting platelets and significantly increased after thrombin or 
CRP treatment. But there was no remarkable difference between ano6+/+ and 
ano6-/- platelets. Besides, the expression of total Orai1 protein in platelets was 
measured utilizing immunofluorescence and confocal microscopy. As is shown 
in Fig.3.1.2C, treatment with thrombin and CRP was followed by an increased 
expression of Orai1 in platelets. However, the expression level in the two 
genotypic platelets was similarly higher. 
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Fig.3.1.2. SOCE and Orai1 expression in ano6
+/+
 and ano6
-/-
 platelets 
A. Arithmetic mean (AM) ± SEM (n = 4) of fluorescence intensity (arb-units) of Fluo-3 in 
ano6
+/+ 
platelets (white bars) and ano6
-/-
 platelets (black bars). Loaded platelets were 
incubated in Ca
2+
 free Tyrody buffer (left bars), and then treated with thapsigargin (1 µM) for 
10 min to deplete Ca
2+
 store (middle bars). Following re-addition of 1 mM CaCl2, platelet 
SOCE was triggered and cytosolic Ca
2+
 concentration reached the maximum after 5 min 
(right bars). ###(p<0.001) represents significant increase from thapsigargin treatment. 
B. Arithmetic mean (AM) ± SEM (n = 4~5) of fluorescence intensity (arb-units) from FACS 
assay of Orai1 abundance at the plasma membrane surface of ano6
+/+ 
platelets (white bars) 
and ano6
-/-
 platelets (black bars) prior to (resting) and following a 15 min exposure to 
thrombin (0.01 U/ml) or CRP (2 µg/ml). ###(p<0.001) indicates significant increase from 
stimulation of the agonists. 
C. Immunofluorescence analysis of total Orai1 protein in ano6
+/+ 
platelets (left panels) and 
ano6
-/-
 platelets (right panels) after a 15 min exposure to thrombin (0.01 U/ml) or CRP (2 
µg/ml). Red: F-actin; green: Orai1. (unpublished) 
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The stimulation of agonists triggered ROS formation by regulating cytosolic Ca2+ 
concentration. Further analyses explored the role of Ano 6 in platelet oxidative 
stress. The abundance of reactive oxygen species (ROS) was measured using 
FACS machine by testing DCFDA fluorescence. As is described in Fig.3.1.3, the 
level of ROS was similarly high in resting platelets from both genotypic (ano6+/+ 
and ano6-/-) mice (Fig.3.1.3A, D). After a 15 minutes exposure to 0.01 U/ml 
thrombin, ROS formation significantly (p<0.001) increased in both ano6+/+ and 
ano6-/- platelets, but the increased magnitude of ROS was significantly (p<0.05) 
less pronounced in Ano 6 deficient platelets than in normal platelets (Fig.3.1.3B, 
D). 15 minutes treatment with 2 µg/ml CRP again led to significant increase of 
ROS formation in both Ano 6 deficient and wild type platelets. Unlike the 
stimulation of thrombin, the effect of CRP on ROS formation was not significantly 
different between ano6-/- platelets and ano6+/+ platelets (Fig.3.1.3C, D) 
 
 
Fig.3.1.3. The effect of Ano 6 on platelet oxidative stress 
A-C. Typical histogram of DCFDA related fluorescence from FACS assay reflected platelet 
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reactive oxidant species (ROS) formation before (A) and after a 15 min exposure to (B) 
0.01U/ml thrombin or (C) 2µg/ml CRP. Grey shadows: ano6
+/+
 platelets, black lines: ano6
-/-
 
platelets. 
D. Arithmetic mean (AM) ± SEM (n = 3~5) of relative fluorescence unit of ROS abundance in 
ano6
+/+
 platelets (white bars) and ano6
-/-
 platelets (black bars).  
###(p<0.001) shows significant increase from the stimulation of thrombin or CRP, *(p<0.05) 
represents significant decrease in ano6
-/- 
platelets.(Liu et al. 2015) 
 
The next experiments addressed the impact of Ano 6 on platelet degranulation. 
The degranulation was quantified using flow cytometry via checking P-selectin 
abundance at the surface of platelet plasma membrane. As is shown in Fig.3.1.4, 
P-selectin abundance was similarly low at the surface of untreated platelets, 
which were isolated respectively from wild type mice and Ano 6 deficient mice 
(Fig.3.1.4A, D). Following a 15 minutes exposure to 0.01 U/ml thrombin, 
P-selectin abundance radically increased in both ano6+/+ and ano6-/- platelets. 
Although there was a slight difference between the growth ranges in the two 
different platelets, it was not statistically significant (Fig.3.1.4B, D). 2 µg/ml CRP 
induced a significant (p<0.001) increase of P-selectin abundance in both 
genotypic (ano6+/+ and ano6-/-) platelets, and the increase was significantly 
blunted in Ano 6 deficient platelets (Fig.3.1.4C, D). 
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Fig.3.1.4. Agonists induced platelet degranulation in ano6
+/+
 and ano6
-/-
 platelets 
A-C. Original histogram from FACS assay reflected the abundance of 
degranulation-dependent P-selectin before (A) and after 15 min stimulation with (B) 
0.01U/ml thrombin or (C) 2µg/ml CRP in platelets. Grey shadows: ano6
+/+
 platelets, black 
lines: ano6
-/-
 platelets. 
D. Arithmetic mean (AM) ± SEM (n = 4~7) of fluorescence intensity unit of P-selectin 
antibody in ano6
+/+
 (white bars) and ano6
-/-
 (black bars) platelets.  
###(p<0.001) indicates significant increase to value from the stimulation of thrombin or CRP, 
*(p<0.05) shows significant decrease from defective Ano 6. (Liu et al. 2015) 
 
The elevated [Ca2+]i can induce activation of platelet integrin αIIbβ3 by the 
mechanism of inside-out signalling pathway. To study the impact of Ano 6 on 
platelet integrin αIIbβ3 activation, further experiments were conducted by 
incubating platelets with the specifically fluorescent-labeled antibody. Like 
P-selectin, the abundance of activated integrin αIIbβ3 at the surface of platelet 
plasma membrane was similarly low in resting platelets of both genotypes 
(ano6+/+ and ano6-/-) (Fig.3.1.5A, D). The related fluorescence of activated 
integrin αIIbβ3 significantly (p<0.001) increased following 0.01 U/ml thrombin 
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treatment for 15 minutes in both ano6+/+ and ano6-/- platelets. Although there was 
a slight difference between the increase ranges in the two different platelets, it 
was not statistically significant (Fig.3.1.5B, D). After a 15 minutes stimulation 
with CRP (2 µg/ml), integrin αIIbβ3 activation remarkably increased in both 
ano6-/- and ano6+/+ platelets. The impact of CRP was again significantly (p<0.05) 
attenuated in ano6-/- platelets than in ano6+/+ platelets (Fig.3.1.5C, D). 
 
 
Fig.3.1.5. The effect of Ano 6 on platelet integrin αIIbβ3 activation 
A-C. Original histogram of antibody related fluorescence from flow cytometric assay 
reflected the activation of platelet integrin αIIbβ3 without stimulation (A) and with a 15 min 
exposure to (B) 0.01U/ml thrombin or (C) 2µg/ml CRP. Grey shadows: ano6
+/+
 platelets, 
black lines: ano6
-/- 
platelets. 
D. Arithmetic mean (AM) ± SEM (n = 4~6) of relative fluorescence intensity (arb-units) of 
activated integrin αIIbβ3 in responds to a 15 min stimulation with thrombin (0.01 U/ml) or 
CRP (2 µg/ml). White bars: ano6
+/+
 platelets, black bars: ano6
-/-
 platelets. 
###(p<0.001) shows significant increase from the treatment of thrombin or CRP, *(p<0.05) 
represents significant attenuation from defective Ano 6. (Liu et al. 2015) 
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Platelet apoptosis is characterized by volume shrinkage and plasma membrane 
scrambling with the translocation of phosphatidylserine (PS) from the inner 
leaflet to the outer leaflet. In order to elucidate the impact of transmembrane 
protein Ano 6 on platelet apoptosis, PS abundance of the platelets was detected 
by flow cytometry utilizing annexin-V-binding. At the same time, platelet volume 
was quantified via the analysis of forward scatter. As is shown in Fig.3.1.6, the 
percentage of annexin-V-binding (marked area) was low in resting platelets in 
vitro and there was no significant difference between the two genotypes 
(Fig.3.1.6A, D). After a 15 minutes simulation with 0.01 U/ml thrombin or 5 µg/ml 
CRP, the percentage of annexin-V labeled platelets significantly (p<0.001) rose 
in both ano6+/+ and ano6-/- genotype. The effect of agonists, however, 
significantly attenuated in ano6-/- platelets in comparison with ano6+/+ platelets 
(Fig.3.1.6B, C, D). 
Fig.3.1.7 shows the platelet volume shrinkage. The volumes of the two types of 
untreated platelets (ano6+/+ and ano6-/-) were almost the same in vitro. 
Incubation with 0.01 U/ml thrombin (15 minutes) was followed by a significant 
(p<0.001) contraction of forward scatter in both Ano 6 deficient platelets and wild 
type platelets. But the effect of thrombin significantly (p<0.01) weakened in Ano6 
deficient platelets. The exposure to 5 µg/ml CRP also resulted in a significant 
(p<0.001) contraction of forward scatter in both genotypic platelets. However, 
the defective Ano 6 significantly (p<0.05) reduced the effect of CRP in platelets. 
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Fig.3.1.6. Ano 6 sensitive PS exposure at the surface of platelets  
A-C. The marked area of overlaid annexin-V binding histogram from FACS assay reflected 
platelet PS exposure in platelets before (A) and after (B) 0.01U/ml thrombin or (C) 5µg/ml 
CRP treatment for 15 min. Grey shadows: ano6
+/+ 
platelets, black lines: ano6
-/-
 platelets. 
D. Arithmetic mean (AM) ± SEM (n = 4~6) of % annexin-V-binding to ano6
+/+ 
(white bars) 
and ano6
-/-
 (black bars) platelets in resting and following a 15 min exposure to thrombin or 
CRP. 
###(p<0.001) indicates significant increase from the stimulation of thrombin or CRP, 
*(p<0.05) and ** (p<0.01) represents significant decrease from defective Ano 6. (Liu et al. 
2015) 
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Fig.3.1.7. The impact of Ano 6 on agonist induced cell shrinkage 
A-C. Original histogram of forward scatter from flow cytometric assay reflected the 
shrinkage of cell volume of ano6
+/+ 
platelets (grey shadows) and ano6
-/-
 platelets (black lines) 
before (A) and after a 15 min stimulation with (B) 0.01U/ml thrombin or (C) 5 µg/ml CRP. 
D. Arithmetic mean (AM) ± SEM (n = 4~6) of relative light intensity unit of forward scatter 
following a 15 min exposure to thrombin or CRP. White bars: ano6
+/+ 
platelets, black bars: 
ano6
-/- 
platelets. 
###(p<0.001) represents significant decrease from the treatment of thrombin or CRP, 
*(p<0.05) shows significant difference between ano6
+/+
 and ano6
-/- 
platelets. (Liu et al. 2015) 
 
To study the influence of Ano 6 with the stimulation of agonists on platelet 
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antibody. Two color analysis of aggregation was performed by flow cytometry. As 
is shown in Fig.3.1.8, the percentage of double-colored events reflecting 
aggregation was similarly low in both genotypic (ano6+/+ and ano6-/-) resting 
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effect of the agonists in ano6+/+ and ano6-/- platelets. 
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Fig.3.1.8. Activation-dependent platelet aggregation in vitro 
A. Representative dot blots from FACS assay reflected the aggregation of ano6
+/+
 platelets 
(a, c) and ano6
-/-
 platelets (b, d) in responds to the stimulation of 0.005 U/ml thrombin in 0 
min (a, b) and 10 min (c, d).  
B. Arithmetic mean (AM) ± SEM (n = 4) of % double-colored events (Q2) reflected platelet 
aggregation in indicated time point after stimulation with thrombin (0.005 U/ml). Black circles: 
ano6
+/+
 platelets, black square: ano6
-/-
 platelets. 
C. Representative dot blots from FACS assay reflected the aggregation of ano6
+/+ 
platelets 
(a, c) and ano6
-/-
 platelets (b, d) in responds to stimulation of 2 µg/ml collagen related 
peptide CRP in 0 min (a, b) and 10 min (c, d).  
D. Arithmetic mean (AM) ± SEM (n = 4) of % double-colored events (Q2) reflected platelet 
aggregation in indicated time point after stimulation with CRP (2 µg/ml). Black circles: 
ano6
+/+
 platelets, black square: ano6
-/-
 platelets.(Liu et al. 2015) 
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3.2 γ-secretase inhibitor DAPT sensitive platelet activation and 
apoptosis 
DAPT, a potent inhibitor of γ-secretase, was employed to block γ-secretase 
activity in platelets isolated from wild type mice. This study explored the effects 
of DAPT on platelet Ca2+ signalling, activation and apoptosis. 
In order to elucidate whether the treatment of γ-secretase inhibitor DAPT modify 
the stimulating effect of CRP on platelet Ca2+ signalling, a series of experiments 
were conducted utilizing FACS machine and Fluo-3 fluorescence. As is depicted 
in Fig.3.2.1A and C, prior to CRP stimulation, the cytosolic Ca2+ concentration 
was similar in DAPT treated platelets and untreated platelets. Following 
exposure to 2 µg/ml CRP, platelet [Ca2+]i significantly increased. But the 
stimulating effect of CRP significantly attenuated after ≥100 seconds stimulation 
in the presence of DAPT (Fig.3.2.1B, C). Further experiment explored the effect 
of DAPT on platelet Ca2+ signaling following stimulation of CRP at the different 
concentrations. As is shown in Fig.3.2.1D, the elevation of platelet [Ca2+]i was 
significantly blunted after 100 seconds’ stimulation with ≥2 µg/ml CRP in the 
DAPT treated platelets. 
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Fig.3.2.1. DAPT sensitive CRP-induced platelet Ca
2+
 response 
A,B. Typical histogram of Fluo-3 fluorescence from flow cytometric assay indicated cytosolic 
Ca
2+
 activity in the control (grey shadows) and DAPT treated (black lines) platelets before 
stimulation (A) and after (B) a 100 sec exposure to CRP (2 µg/ml).  
C,D. Arithmetic mean (AM) ± SEM (n = 4) of fluorescence intensity (arb-units) of activated 
Fluo-3 reflected (C) the influence of CRP (2 µg/ml) at different stimulation times and (D) the 
impact of CRP at different concentrations following a 100 seconds stimulation. 
White bars: control platelets, black bars: 10 µM DAPT treated platelets. 
###(p<0.001) denotes significant increase from CRP stimulation, **(p<0.01) and *** 
(p<0.001) denotes significant decrease from the treatment of DAPT.(Liu et al. 2016) 
 
In response to CRP stimulation, the elevation of [Ca2+]i significantly decreased in 
DAPT treated platelets. This indicated that when γ-secretase activity was 
inhibited in platelets, store-operated Ca2+ entry (SOCE) might also be impaired. 
Thus, platelet [Ca2+]i was measured prior to treatment and after a 10 minutes 
exposure to 1 µM thapsigargin. As is shown in Fig.3.2.2A, following thapsigargin 
treatment, platelet [Ca2+]i significantly increased in the absence of extracellular 
Ca2+, and the effect of γ-secretase inhibitor DAPT was negligible. 5 minutes from 
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55 
the re-adding of 1 mM CaCl2, platelet [Ca
2+]i further increased, and the effect of 
thapsigargin was significantly blunted in DAPT treated platelets.  
To explore whether Orai1/STIM1 was required for the impaired CRP induced 
Ca2+ response in DAPT treated platelets, Western blot was performed to 
measure the expression of Orai1 and STIM1 in platelets. As is shown in 
Fig.3.2.2B and C, the expression of STIM1 was similar before and after CRP 
stimulation in the absence and presence of DAPT. Fig.3.2.2B and D showed that 
the expression of Orai1 significantly increased after a 15 minutes treatment with 
2 µg/ml CRP treatment. However, the effect of CRP remarkably attenuated in the 
presence of 10 µM γ-secretase inhibitor DAPT. 
 
 
Fig.3.2.2. SOCE and CRP induced Orai1/STIM1 expression in DAPT sensitive platelets 
A. Arithmetic mean (AM) ± SEM (n = 4~5) of fluorescence unit (arb-units) of activated Fluo-3 
reflected [Ca
2+
]i in the control platelets (white bars) and 10µM DAPT treated platelets (black 
bars). Fluo-3 loaded platelets were incubated in Ca
2+
 free Tyrody buffer (left bars), and then 
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treated with thapsigargin (1 µM) for 10 min to deplete Ca
2+
 store (middle bars). Following 
re-addition of 1 mM CaCl2, platelet SOCE was triggered and cytosolic Ca
2+
 concentration 
reached the maximum after 5 min (right bars). 
B. The expression of total Orai1/STIM1 protein before and after exposure to CRP (2µg/ml) 
for 15 min was analyzed by Western blots in the presence and absence of DAPT. 
C,D. Arithmetic mean (AM) ± SEM (n = 4) of STIM1 (C) and Orai1 (D) protein abundance in 
the control platelets (white bars) and 10 µM DAPT treated platelets (black bars) before and 
after a 15 min exposure to CRP (2µg/ml). 
###(p<0.001) represents significant increase from thapsigargin treatment, *(p<0.05) 
represents significant decrease from DAPT treatment. (unpublished) 
 
The expression of Orai1 protein at the surface of platelet plasma membrane was 
quantified utilizing fluorescence conjugated antibody and flow cytomerty. As is 
shown in Fig.3.2.3A and D, the Orai1 abundance at the surface of resting 
platelets was similar in the absence and presence of DAPT. Upon the stimulation 
of CRP (2 µg/ml), Orai1 abundance significantly (p<0.001) increased in both 
DAPT treated platelets and untreated platelets. After a 100 seconds treatment, 
although the stimulating effect of CRP was slightly blunted in 10 µM DAPT 
treated platelets, it was not significantly different in comparison with the control 
platelets (Fig.3.2.3B, D). After 15 minutes treatment, the increase of Orai1 
protein abundance significantly (p<0.01) decreased in DAPT treated platelets 
(Fig.3.2.3C, D). Fig.3.2.3E showed the impact of DAPT under different 
concentrations on Orai1 abundance. The expression level of Orai1 protein at the 
surface of resting platelets was almost the same in the presence of 1~ 20 µM 
DAPT. The increase of Orai1 abundance following a 100 seconds exposure to 2 
µg/ml CRP was also similar in the presence of ≤10 µM DAPT. The stimulating 
effect of CRP on platelets, however, was significantly (p<0.05) blunted in the 
presence of 20 µM DAPT. 
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Fig.3.2.3. Orai1 protein abundance at the surface of platelets 
A,B,C. Typical histogram overlays of antibody fluorescence from FACS assay reflected 
Orai1 protein abundance at the platelet surface before (A) and after a (B)100 sec or (C)15 
min stimulation with CRP (2 µg/ml). Grey shadows: control platelets, black lines: 10 µM 
DAPT treated platelets. 
D. Arithmetic mean (AM) ± SEM (n = 4) of the fluorescence unit of Orai1 abundance at the 
surface of platelets before (left bars) and after a (middle bars) 100 sec or (right bars) 15 min 
stimulation with 2µg/ml CRP. White bars: control platelets, black bars: 10 µM DAPT treated 
platelets. 
E. Arithmetic mean (AM) ± SEM (n = 5) of the fluorescence unit of Orai1 abundance in the 
control platelets (white bar) and the different concentrations (1, 5, 10 or 20 µM) DAPT 
treated platelets (filled bar) before (left bars) and after a 100 sec (right bars) stimulation with 
CRP (2 µg/ml).  
###(p<0.001) indicates significant increase from CRP stimulation, *(p<0.05) and ** (p<0.01) 
represents significant decrease from DAPT treatment. (Liu et al. 2016) 
 
The elevation of [Ca2+]i lead to platelet degranulation, which is evaluated 
effectively by detecting the expression level of P-selectin at the platelet surface. 
In order to study the effect of DAPT on platelet degranulation, P-selectin 
abundance was detected utilizing flow cytometry and fluorescence labeled 
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58 
antibody. As is illustrated in Fig.3.2.4A and C, P-selectin abundance at the 
surface of resting platelets was nearly the same in the absence and presence of 
10 µM DAPT. After stimulation with CRP (2 µg/ml), P-selectin abundance 
significantly (p<0.001) increased in DAPT treated and untreated platelets. But 
the stimulating effect of CRP significantly (p<0.05) abated in the presence of 
DAPT (Fig.3.2.4B, C) 
Likewise, the effect of DAPT on platelet activation was evaluated by detecting 
related-fluorescence of integrin αIIbβ3 antibody. Fig.3.2.4D and F showed the 
activation of integrin αIIbβ3 in resting platelets was negligible, and there was no 
remarkable distinction between DAPT treated and untreated platelets. The 
stimulation of platelets with CRP significantly increased the activation of integrin 
αIIbβ3. However, the preincubation of DAPT remarkably inhibited the increase of 
integrin activation (Fig.3.2.4E, F). 
 
 
Fig.3.2.4. DAPT sensitive platelet degranulation and integrin αIIbβ3 activation 
A,B. Original histogram of fluorescence from FACS assay reflected the abundance of 
degranulation-dependent P-selectin before (A) and after a (B) 15 min stimulation with 2 
resting CRP
0
10
20
30
40
Control
DAPT 10µM
P
-s
e
le
c
ti
n
[M
F
I] *
###
A B 
P-selectin abundance
100 101 102 103 104
C
o
u
n
ts
0
3
0
6
0
9
0
1
5
0
1
2
0
C
P-selectin abundance
100 101 102 103 104
C
o
u
n
ts
0
3
0
6
0
9
0
1
5
0
1
2
0
resting CRP
0
50
100
150
200
Control
DAPT 10µM
A
c
ti
v
a
te
d
 i
n
te
g
ri
n
 α
II
b
β
3
*
###
D E
Integrin abundance
100 101 102 103 104
C
o
u
n
ts
0
3
0
6
0
9
0
1
5
0
1
2
0
F
Integrin abundance
100 101 102 103 104
C
o
u
n
ts
0
3
0
6
0
9
0
1
5
0
1
2
0
59 
µg/ml CRP in platelets. Grey shadows: control platelets, black lines: 10 µM DAPT treated 
platelets. 
C. Arithmetic mean (AM) ± SEM (n = 4) of fluorescence intensity unit of anti-P-selectin 
antibody in platelets. White bars: control platelets, black bars: 10 µM DAPT treated platelets.  
D,E. Typical histogram of fluorescence from FACS assay reflected the activation of integrin 
αIIbβ3 before(D) and after a (E) 15 minutes stimulation with 2 µg/ml CRP in platelets. Grey 
shadows: control platelets, black lines: 10 µM DAPT treated platelets. 
F. Arithmetic mean (AM) ± SEM (n = 4) of relative fluorescence (arb-units) of the activated 
integrin αIIbβ3 in platelets. White bars: control platelets, black bars: 10 µM DAPT treated 
platelets  
###(p<0.001) represents significant increase from CRP stimulation, *(p<0.05) represents 
significant decrease from DAPT treatment. (Liu et al. 2016) 
 
The stimulation of CRP inducted ROS generation by regulating platelet cytosolic 
Ca2+ concentration. Further experiments investigated the effect of γ-secretase 
inhibitor DAPT on platelet oxidative stress utilizing DCFDA fluorescence. As is 
revealed by flow cytometry (Fig.3.2.5), following the stimulation of CRP (2 µg/ml), 
ROS formation gradually increased and reached a steady level after 9 minutes. 
However, the increase of ROS in DAPT treated platelets was significantly 
inhibited after 7 minutes stimulation. 
 
Fig.3.2.5. DAPT sensitive CRP-induced ROS formation  
Arithmetic mean (AM) ± SEM (n = 4) of ROS abundance related fluorescence (arb-units) in 
platelets following 2 µg/ml CRP treatment. 
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Black circles: control platelets, black square: 10 µM DAPT treated platelets 
*(p<0.05) indicates significant decrease in the presence of DAPT. (Liu et al. 2016) 
 
The loss of mitochondrial membrane potential (Δψm) is a very important marker 
for apoptosis of various kinds of cells. To further understand the effect of DAPT 
on platelet apoptosis, Δψm was tested following CRP treatment using flow 
cytometry and cationic dye TMRE (tetramethylrhodamine, ethyl ester 
perchlorate). As the result, Δψm was similar in the resting platelets with and 
without DAPT treatment (Fig.3.2.6A, C). TMRE fluorescence analysis showed 
that platelet Δψm significantly declined following 5 µg/ml CRP treatment. 
However, the stimulating effect of CRP again pronouncedly abated in the 
presence of DAPT (Fig.3.2.6B, C). 
 
 
Fig.3.2.6. The effect of DAPT on platelet mitochondrial depolarization 
A,B. Original histogram of TMRE fluorescence from FACS assay reflected the loss of 
platelet mitochondrial membrane potential (Δψm) before (A) and after CRP (5 µg/ml) 
stimulation (B). Grey shadows: control platelets, black lines: 10 µM DAPT treated platelets. 
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61 
C. Arithmetic mean (AM) ± SEM (n = 4) of TMRE fluorescence (arb-units) of Δψm before 
(left bars) and after (right bars) 5µg/ml CRP stimulation in the control (white bars) and DAPT 
(black bars) treated platelets. 
###(p<0.001) represents significant decrease from CRP stimulation, **(p<0.01) represents 
significant difference from DAPT treatment. (Liu et al. 2016) 
 
Ca2+-dependent phospholipid scrambling contributes to both platelet activation 
and apoptosis. Thus, a series of experiments were conducted to test the effect of 
DAPT on platelet PS exposure and cell shrinkage utilizing flow cytometry. As is 
shown in Fig.3.2.7A and C, the percentage of annexin-V-binding (marked area) 
was negligible in resting platelets, irrespective of the preincubation of 10 µM 
DAPT. The stimulation of CRP (5 µg/ml) for 10 minutes significantly enhanced 
platelet PS exposure. However, the increased percentage of annexin-V-binding 
was significantly downregulated in the presence of DAPT (Fig.3.2.7B, C). 
The shrinkage of platelet volume was evaluated via the analysis of forward 
scatter. As is illustrated in Fig.3.2.7D and F, the size of resting platelets was 
similar in the absence and presence of γ-secretase inhibitor DAPT. The 
exposure to CRP (5 µg/ml) for 10 minutes caused significant platelet shrinkage, 
but the reduction of platelet volume was again significantly (p<0.05) attenuated 
by DAPT (Fig.3.2.7E, F). 
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Fig.3.2.7. DAPT sensitive platelet membrane scrambling and forward scatter 
A,B. Typical histogram of platelet annexin-V-binding from FACS assay reflected PS 
exposure before (A) and after (B) a 10 minutes exposure to 5 µg/ml CRP. 
Grey shadows: control platelets, black lines: 10 µM DAPT treated platelets. 
C. Arithmetic mean (AM) ± SEM (n = 4) of % annexin-V binding (marked area) of the control 
(white bars) and DAPT (black bars) treated platelets before (left bars) and after (right bars) a 
10 min exposure to 5 µg/ml CRP. 
D,E. Original histogram of platelet forward scatter from flow cytometric assay reflected 
shrinkage of cell volume in the resting (D) and following (E) a 10 min exposure to 5 µg/ml 
CRP. 
Grey shadows: control platelets, black lines: 10 µM DAPT treated platelets. 
F. Arithmetic mean (AM) ± SEM (n = 4) of light intensity related unit of forward scatter before 
(left bars) and after (right bars) stimulation with 5 µg/ml CRP for 10 min in the control (white 
bars) and DAPT (black bars) treated platelets. 
###(p<0.001) indicates significant difference from CRP stimulation, *(p<0.05) represents 
significant difference from DAPT treatment. (Liu et al. 2016) 
 
Further experiment was performed to explore the influence of DAPT on platelet 
aggregation. To this end, platelets were stained with CD9-APC and CD9-PE, 
and then the fluorescence was detected on FACS machine. As is demonstrated 
in Fig.3.2.8, the stimulation of CRP (2 µg/ml) led to the rapid aggregation of 
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63 
platelets, which reached a steady level after 4 minutes. The increased 
percentage of double-colored events significantly decreased as the result of 
DAPT treatment. 
 
 
Fig.3.2.8. Activation dependent platelet aggregation in the presence of DAPT 
A. Representative dot blots from FACS assay reflected the platelet aggregation of the 
control group (a, c) and DAPT preincubated group (b, d) in responds to the stimulation of 2 
µg/ml CRP in 0 min (a, b) and 4 min (c, d). 
B. Arithmetic mean (AM) ± SEM (n = 4) of % double-colored evens (Q2) reflecting platelet 
aggregation following stimulation with CRP in indicated time point. Black circles: control 
platelets, black square: DAPT treated platelets. 
*(p<0.05) represents significant decrease from DAPT treatment. (Liu et al. 2016) 
 
To explore whether the impaired platelet activation upon CRP treatment led to 
the reduce of thrombus formation in the presence of DAPT, further experiments 
were conducted to test thrombus formation on collagen coated glass surfaces 
under the condition of high shear rates. As is illustrated in Fig.3.2.9, the 
thrombus formation slightly decreased in the presence of 10 µM DAPT and 25 
µM DAPT. However, the difference between the control group and DAPT treated 
groups was not statistically significant difference. 
A B
Control
DAPT 10µM
Time (minutes)
%
 d
o
u
b
le
-c
o
lo
re
d
 e
v
e
n
ts
0 2 4 6 8 10
0
10
20
30
* * *
10
0
10
1
10
2
10
3
10
4
CD9 PE
10
0
10
1
10
2
10
3
10
4
C
D
9
 A
P
C
Q1 Q2
Q4Q3
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
a b
dc
C
D
9
 A
P
C
C
D
9
 A
P
C
C
D
9
 A
P
C
CD9 PE
CD9 PECD9 PE
Q1 Q2
Q4Q3
Q1 Q2
Q4Q3
Q1 Q2
Q4Q3
64 
 
Fig.3.2.9. Platelet thrombus formation with DAPT treatment in vitro 
Whole Blood was perfused over a collagen-coated glass surface before (upper left) and 
after a 30 min pretreatment with 10 µM DAPT (upper right) and 25 µM DAPT (lower left) 
under the high wall shear rates (1700s
-1
).  
Data shows arithmetic mean (AM) ± SEM (n=5, lower right) of thrombus area. (unpublished) 
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4. Discussion 
It is well known that anucleate platelets participate in a variety of 
pathophysiological processes including atherosclerosis, thrombosis and 
hemostasis, while platelet activation is essential for achieving these processes 
(Harrison 2005). Cytosolic Ca2+ plays a vital role in the complex activation 
mechanism of platelets, which contributes to platelet degranulation, integrin 
activation, PS exposure and subsequent platelet aggregation as well as 
thrombus formation (Bergmeier and Stefanini 2009). Besides, the increase of 
intracellular Ca2+ concentration can trigger apoptotic process of platelets and 
regulate platelet oxidative stress (Rakesh et al. 2014). According to recent 
researches, the entry of extracellular Ca2+ mainly results from Orai1/STIM1 
mediated store-operated Ca2+ entry (SOCE) in platelets (Lang et al. 2013). 
This study explored the role of Anoctamin 6 (Ano 6) and γ-secretase in 
regulating platelet Ca2+ signaling, relative platelet activation and apoptosis, 
which were accomplished respectively by using an Ano 6 deficient mice model 
and a γ-secretase specific inhibitor DAPT. 
4.1 The effect of defective Ano 6 on platelet activation and 
apoptosis 
The membrane protein Ano 6 (Tmem16F) is a member of the Anoctamin 
protein family, which plays a variety of roles in different cells and was 
described as Ca2+-regulated nonselective Ca2+ permeable cation channel or 
Ca2+-dependent and a volume-regulated Cl− channel (Kunzelmann et al. 2014). 
Defective Ano 6 is strongly associated with Scott syndrome, which is a rare 
inherited bleeding disorder resulting from impaired platelet phospholipid 
scrambling and subsequent decreased generation of thrombin (Picollo et al. 
2015). The present observations unravel a subtle but remarkable influence of 
Ano 6 on platelet activation and apoptosis in the wake of thrombin or collagen 
related peptide (CRP) treatment. Prior to activation, Intracellular Ca2+ 
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concentration ([Ca2+]i), platelet degranulation (P-selectin abundance), reactive 
oxygen species (ROS), phosphatidylserine (PS) exposure, αIIbβ3 integrin 
activation, and cell volume were similar in platelets isolated from Ano 6 
deficient mice (ano6-/-) and corresponding wild-type mice (ano6+/+). The 
stimulation of thrombin and CRP resulted in the significant increase of [Ca2+]i 
and platelet oxidative stress, and triggered integrin αIIbβ3 activation and 
platelet degranulation. However, the effects of these agonists were less 
pronounced in ano6-/- platelets than in ano6+/+ platelets. The increase of [Ca2+]i 
is a key event during the platelet activation (Varga-Szabo et al. 2011), which 
further triggers platelet degranulation, adhesion and aggregation, thus 
supporting the development of thrombosis (Bergmeier and Stefanini 2009). 
Orai1/STIM1 mediated store-operated Ca2+ entry (SOCE) is considered as the 
primary pathway for agonist induced Ca2+ influx (Prakriya and Lewis 2015). 
However, platelet SOCE was similar in platelets from ano6-/- than in ano6+/+ 
mice. The increased Orai1 expression after thrombin and CRP stimulation at 
the surface of plasma membrane and in whole cells was not significantly 
different between both genotypic platelets. These data indicate that the 
impaired Ca2+ response in Ano 6 deficient platelets does not result from the 
activation of STIM1 mediated Orai1 channel. According to Viitanen’s report 
(Viitanen et al. 2013), Ano 1, another member of the Anoctamin protein family, 
functionally coupled with transient receptor potential channel 2 (TRPC2) 
channel in thyroid cells. TRPC2 is an important Ca2+-permeable cation 
channel and mediate Ca2+ influx in many types of cells (Pedersen et al. 2005). 
Whether Ano 6 blunting thrombin and CRP evoked Ca2+ influx by interacting 
with other ion channels in platelets calls for further study. 
The treatment of thrombin and CRP further led to platelet PS translocation and 
cell shrinkage, which are key events in apoptosis that limit the life span of 
circulating platelets (Kile 2014).The stimulation of platelet apoptosis may 
similarly be secondary to the increase of [Ca2+]i (Varga-Szabo et al. 2011), 
which is known to stimulate cell membrane phospholipid scrambling with PS 
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translocation (Borst et al. 2012), (Mahaut-Smith 2013), (Harper and Poole 
2011), (Mushtaq et al. 2011). The present research shows that PS exposure of 
platelets depends partly on the presence of membrane protein Ano 6. Besides, 
the agonists (thrombin or CRP) induced platelet shrinkage also relies in part on 
the activity of Ano 6 protein. It is conceivable that Ano 6 mediates Cl- exit as a 
Ca2+ dependent Cl- channel in platelets (Kunzelmann et al. 2014) and thus 
supports the loss of ions and osmotically obliged water (Lang and Hoffmann 
2012).  
Upon thrombin and CRP stimulation, the increase of [Ca2+]i was significantly 
blunted in platelets from ano6-/- mice. It is important to note that the role of 
Ano6 has been described as a nonselective and Ca2+ permeable channel in 
platelets, which could be relevant to the present results (Jin et al. 2013), (Yang 
et al. 2012), (Yu et al. 2015). However, It should be pointed out that the defect 
of phospholipid scrambling in ano6-/- platelets was not caused by impaired 
Ca2+ influx through Ano 6 protein (Kunzelmann et al. 2014). It is possible that 
Ano 6 protein indirectly regulates platelet Ca2+ signaling, similar to the case of 
Ano 1 (Tian et al. 2012). 
PS exposure has double effects on platelets. On the one hand, PS exposing 
platelets can bind to macrophages and then be eliminated through engulfment 
(Badlou et al. 2006). On the other hand, PS at the platelet surface stimulates 
blood coagulation and thus contributes to the hemostasis of injured blood 
vessel (Lhermusier et al. 2011). Besides, PS exposure also stimulates the 
generation of thrombin and platelet pro-coagulant activity (Harper and Poole 
2011), (Mushtaq et al. 2011), (Wolfs et al. 2005), (Mahaut-Smith 2013). 
An early clinical study investigated the hemostasis parameters of several Scott 
patients and the platelet number was normal in the blood of the patients (Toti et 
al. 1996). According to this research, however, the platelet number was higher 
in the blood of ano6-/- mice than that of ano6+/+ mice. It is tempting to speculate 
that the reduced sensitivity of PS translocation to the stimulation of agonists is 
followed by reduced clearance of PS exposing platelets from circulating blood. 
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In conclusion, the present study shows that Ano 6 contributes to both platelet 
activation and apoptosis (Fig 4.1.1). Ano 6 deficiency attenuates the effect of 
thrombin and CRP on Ca2+ influx, integrin activation, platelet degranulation, as 
well as PS exposure and platelet shrinkage. Thus, Ano 6 is a novel element in 
the regulation of platelet function and survival. 
 
 
 
Fig 4.1.1 Synopsis of Ano6 sensitive platelet functions (Liu et al. 2015) 
 
4.2 DAPT sensitive platelet activation and apoptosis 
γ-secretase is a complex composed of multiple subunits, which cleaves many 
type I membrane proteins, such as Notch 1-4, CD44, APP, and so on, as an 
intramembrane-cleaving proteases (i-CLiPs) in various kinds of cells (Zhang et 
al. 2014), (Kopan and Ilagan 2004), (Nagano and Saya 2004). DAPT, 
N-[N-(3,5-difluorophenacetyl)-Lalanyl]-S-phenylglycinet-butyl ester, was 
reported as a γ-secretase specific inhibitor and wildly used in the related 
researches of functions and signaling of γ-secretase and its target proteins 
(Hosaka et al. 2014), (Su et al. 2016), (Sigounas et al. 2017), (Terabe et al. 
2016). 
The present study uncovers a novel effect of the γ-secretase inhibitor DAPT, 
i.e. the attenuation of platelet activation in responding to CRP stimulation. Prior 
to CRP stimulation, the impact of DAPT on the properties of the tested platelet 
was negligible. In contrast, DAPT treatment significantly weakens the effect of 
CRP on integrin activation, platelet degranulation, cell membrane scrambling 
as well as cell shrinkage. PS translocation to the surface of platelet plasma 
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membrane upon membrane phospholipid scrambling is expected to foster the 
procoagulant function of platelets, which is a key event in hemostasis 
(Lhermusier et al. 2011).  
According to Terabe’s report (Terabe et al. 2016), γ-secretase inhibitor DAPT 
effectively inhibited the fragmentation of CD44 in bovine articular chondrocytes. 
The effects of DAPT in platelets could be explained as follows: the inhibition of 
γ-secretase is expected to enhance the CD44 protein abundance and thus 
strengthen the inhibitory effects of CD44 on platelet activation and apoptosis 
(Fig 4.2.1) (Liu et al. 2016).  
 
 
Fig 4.2.1 A potential mechanism of DAPT sensitive platelet 
activation and apoptosis 
 
Platelet activation, apoptosis and thrombus formation is in large part 
secondary to the increase of [Ca2+]i (Lang et al. 2013), and the negative 
regulations of DAPT on platelet activation and plasma membrane scrambling 
is paralleled by a significantly attenuated increase of [Ca2+]i. CRP evoked Ca
2+ 
influx mainly derived from Orai1/STIM1 mediated SOCE in platelets (Prakriya 
and Lewis 2015), (Lang et al. 2013). In rat neurons, the expression of mutated 
presenilin-1 not only inhibited γ-secretase activity, but also caused prolonged 
γ-secretase CD44
DAPT
Orai1/STIM1 mediated SOCE
[Ca2+]i
PS P-selectin ROSintegrin
70 
SOCE upon the stimulation of cyclopiazonic acid. Further experiments showed 
that the neurons treated with γ-secretase inhibitor also displayed slightly 
prolonged SOCE (Shideman et al. 2009). This study shows that γ-secretase 
inhibitor DAPT treated platelets display impaired SOCE. Besides, the 
expression of Orai1 protein with CRP stimulation in the whole cells and at the 
platelet surface is significantly blunted by DAPT. Correspondingly, platelet 
SOCE is strengthened in CD44 deficient platelets (Liu et al. 2016). This study 
enlightens that the effect of DAPT on Ca2+ signaling in platelets is likely to be 
achieved via the γ-secretase/CD44 pathway. 
Oxidative stress could be partly due to the increase of [Ca2+]i upon CRP 
treatment. This study shows that the treatment of γ-secretase inhibitor DAPT 
blunts the increase of platelet reactive oxygen species (ROS) formation upon 
CRP treatment. The oxidative stress of platelets is paralleled by mitochondrial 
depolarization. Following this thought, CD44 counteracts oxidative stress 
(Yoshida and Saya 2014) and could thus contribute to or even account for the 
attenuation of ROS formation by DAPT. However, amyloid-β (Aβ) peptide 
could be another factor for ROS formation in platelets. It is derived from APP, 
which is cleaved by γ-secretase (Haass et al. 2012). Gowert’s research 
showed that Aβ stimulation could induce platelet ROS generation in vitro 
(Gowert et al. 2014).  
The increased cytosolic Ca2+ triggers platelet activation, which supports the 
development of arterial thrombosis (Bergmeier and Stefanini 2009). The 
increase of [Ca2+]i further leads to platelet phospholipid scrambling with the 
translocation of PS to the surface of cell plasma membrane (Borst et al. 2012), 
(Mushtaq et al. 2011). The attenuation of CRP-induced PS exposure may thus 
be due to the decrease of Ca2+ influx in DAPT treated platelets. As is described 
before, PS exposure at the platelet surface contributes to the formation of 
clotting factor complex and thus the generation of thrombin, which in turn 
augments the activation of platelets (Harper and Poole 2011), (Wolfs et al. 
2005), (Mushtaq et al. 2011). Besides, the exposed PS is further bound to the 
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receptors on the surface of macrophages, which leads to platelets’ eventual 
engulfment by macrophages (Badlou et al. 2006). Both platelet activation and 
apoptosis contribute to the stimulation of platelet aggregation, which is again 
slightly, but significantly inhibited by γ-secretase inhibitor DAPT. 
Following stimulation, platelets release the CD44 activating ligand 
macrophage migration inhibitory factor (MIF) (Strussmann et al. 2013), which 
inhibits platelet activation and plasma membrane scrambling as part of an 
autocrine negative feedback loop. Chatterjee’s study shows that MIF 
effectively limits activation-induced apoptosis of platelets through interaction 
with CXCR7 (Chatterjee et al. 2014). CD44 contributes to inflammatory 
disease via MIF signaling, and is deemed as a target for the treatment of such 
diseases (Sanchez-Nino et al. 2013). To the extent that γ-secretase degrades 
CD44 via activity of intramembrane-cleaving proteases (McManus et al. 2014), 
(Nagase et al. 2011), (Nagase and Nakayama 2013), pharmacological 
inhibition of γ-secretase activity could enhance the negative feedback loop and 
thus attenuate platelet activation and membrane phospholipid scrambling.  
Nonetheless, although CD44 participates in the regulation of MIF signaling 
(Merk et al. 2012), (Sanchez-Nino et al. 2013), and the activation of platelets 
by several agonists such as CRP is augmented in CD44 deficent platelets (Liu 
et al. 2016), the observed blunting effect of DAPT on platelet activation and 
cell membrane scrambling is not necessarily caused by increased CD44 
abundance and activity.  
In conclusion, the γ-secretase inhibitor DAPT blunts platelet SOCE, the 
CRP-induced increase of Orai1 expression, cytosolic Ca2+ activity, ROS 
generation, integrin activation, platelet degranulation, the translocation of PS 
to the platelet surface and cell shrinkage, and thus attenuates platelet 
activation and apoptosis.  
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5. Summary 
It is well known that Ca2+ contributes to various steps of platelet activation and 
apoptosis. The increased plasma Ca2+ mainly derives from store release and 
Orai1/STIM1 mediated store-operated Ca2+ entry (SOCE). This study explores 
the effects of Anoctamin 6 (Ano 6) and γ-secretase inhibitor DAPT on platelet 
Ca2+ signaling, activation and apoptosis. 
Ano 6 was described as a Ca2+ activated Cl- channel in many kinds of cells. 
Defective Ano 6 underlies Scott syndrome, which is a rare bleeding disorder 
resulting from impaired platelet phospholipid scrambling. The present study 
shows that platelet number was remarkably higher in the blood from ano6-/- 
mice than that from ano6+/+ mice. There was no significant difference in 
platelet SOCE and Orai1 abundance between the two genotypes. Besides, 
phosphatidylserine (PS) exposure, ROS abundance, platelet degranulation, 
integrin αIIbβ3 activation and intracellular Ca2+ concentration ([Ca2+]i) were 
similar in resting platelets from ano6+/+ mice and ano6-/- mice. The stimulation 
of CRP or thrombin resulted in the significant increase of [Ca2+]i, ROS 
formation, integrin αIIbβ3 activation and P-selectin abundance, and triggered 
PS exposure as well as cell shrinkage in both genotypes. However, all effects 
were significantly attenuated in ano6-/- platelets compared with that in ano6+/+ 
platelets. In conclusion, defective Ano 6 attenuates CRP or thrombin induced 
platelet activation and apoptosis. 
DAPT inhibits γ-secretase complex, which cleaves membrane protein CD44, a 
negative regulator of platelet activation and apoptosis. The present research 
showed that platelet SOCE was significantly attenuated in the presence of 
DAPT. In addition, the exposure of platelets to CRP was followed by significant 
increase of [Ca2+]i, Orai1 abundance, integrin αIIbβ3 activation, platelet 
degranulation, mitochondrial depolarization, cell shrinkage, annexin-V-binding, 
ROS formation and aggregation. However, all effects of CRP were inhibited by 
DAPT. In conclusion, the γ-secretase inhibitor DAPT counteracts the CRP 
induced platelet activation, apoptosis and aggregation. 
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6. Zusammenfassung 
Es ist wohlbekannt, dass Ca2+ vielfältig zu zahlreichen Schritten der 
Thrombozytenaktivierung und -apoptose beiträgt. Das erhöhte Plasma-Ca2+ ist 
hauptsächlich durch Speicherfreisetzung und Orai1/STIM1-vermittelten 
speicherabhängigen Ca2+-Einstrom (SOCE) bedingt. Diese Studie untersucht 
die effekte von Anoctamin 6 (Ano 6) und dem γ-Sekretase-Inhibitor DAPT auf 
den Ca2+-Signalweg, Aktivierung und Apoptose von Thrombozyten.  
Ano 6 wurde in vielen Zellarten als Ca2+-gesteuerter Cl--Kanal beschrieben. 
Defektes Ano 6 liegt dem Scott Syndrom, einer seltenen 
Blutgerinnungsstörung, die aus einer gestörten Umlagerung der Phospholipide 
an der Thrombozyten-Zellmembran hervorgeht, zugrunde. Die vorliegende 
Arbeit zeigt, dass die Anzahl der Thrombozyten auffallend höher im Blut von 
ano6-/--Mäusen als von ano6+/+-Mäusen war. SOCE und Orai1-Menge der 
Thrombozyten waren in beiden Genotypen nicht signifikant verschieden. 
Außerdem waren die Phosphatidylserin (PS)-Exposition, ROS-Menge, 
Plättchendegranulation, Integrin αIIbβ3-Aktivierung und intrazelluläre 
Ca2+-Konzentration ([Ca2+]i) in ruhenden Thrombozyten von ano6
+/+- and 
ano6-/--Mäusen ähnlich. Die Stimulation durch CRP oder Thrombin erhöhte 
signifikant die [Ca2+]i, P-Selektin-Menge, Integrin αIIbβ3-Aktivierung und 
Bildung von ROS und triggerte die PS-Exposition sowie Zellschrumpfung in 
beiden Genotypen. Jedoch verminderten sich alle Effekte deutlich in ano6-/-- 
gegenüber ano6+/+-Thrombozyten. Schlussfolgernd vermindert defektes Ano 6 
die durch CRP oder Thrombin induzierte Aktivierung und Apoptose von 
Thrombozyten. 
DAPT inhibiert den γ-Sekretase-Komplex, welches CD44, einen negativen 
Regulator der Thrombozytenaktivierung und -apoptose, spaltet. Die 
vorliegende Arbeit zeigt, dass SOCE in Thrombozyten in Anwesenheit von 
DAPT signifikant gesenkt wurde. Zusätzlich führte die Exposition der 
Thrombozyten gegenüber CRP zu einem beachtlichen Zuwachs an [Ca2+]i, 
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Integrin αIIbβ3-Aktivierung, Thrombozyten-Degranulation, mitochondrialer 
Depolarisation, Orai1 Menge, ROS-Bildung, Annexin-V-Bindung, 
Zellschrumpfung und -aggregation. Alle Effekte von CRP wurden jedoch von 
DAPT inhibiert. Schlussfolgernd wirkt der γ-Sekretase-Inhibitor DAPT einer 
CRP-induzierten Thrombozytenaktivierung, -apoptose und -aggregation 
entgegen. 
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